<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002459</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>351</s160></s100><s200><s210>1</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 1aggttaccta acggagcgag ga                                              22</s400><s200><s210>2</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 2tgggtactgg atcagtcttc ca                                              22</s400><s200><s210>3</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 3tagttgctga gcgtcgtcag gga                                             23</s400><s200><s210>4</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 4cagcactccc tgacgacgct ca                                              22</s400><s200><s210>5</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 5cgagagacgc ggcgcggcca ttg                                             23</s400><s200><s210>6</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 6ccgcgtctct cgcggggggg tgg                                             23</s400><s200><s210>7</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 7cgggagtgga aaggggcggg gca                                             23</s400><s200><s210>8</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 8cccgcgttgt cggatcagca gac                                             23</s400><s200><s210>9</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 9acgcggggga gccgggagtg ga                                              22</s400><s200><s210>10</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 10ccgacaacgc gggggagccg gg                                              22</s400><s200><s210>11</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 11agaccgattc tgggcgctgc gtc                                             23</s400><s200><s210>12</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 12gcccagaatc ggtctgctga tcc                                             23</s400><s200><s210>13</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 13tgggcgctgc gtcgcatcgg tg                                              22</s400><s200><s210>14</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 14gcgtcgcatc ggtggcaggt aa                                              22</s400><s200><s210>15</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 15gcgacgcagc gcccagaatc gg                                              22</s400><s200><s210>16</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 16gatgcgacgc agcgcccaga atc                                             23</s400><s200><s210>17</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 17gatgcgacgc agcgcccaga atc                                             23</s400><s200><s210>18</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 18catcggtggc aggtaagcgg gc                                              22</s400><s200><s210>19</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 19ggtaagcggg ctgctgaagc cag                                             23</s400><s200><s210>20</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 20aagcgggctg ctgaagccag gcc                                             23</s400><s200><s210>21</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 21agcttgacga cggaaggctg agt                                             23</s400><s200><s210>22</s210><s211>24</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 22gccgagcttg acgacggaag gctg                                            24</s400><s200><s210>23</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 23cggctcactg cgcctctcgg ggc                                             23</s400><s200><s210>24</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 24gagccgagct tgacgacgga ag                                              22</s400><s200><s210>25</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 25tctcggggcc ttgaggccac ggg                                             23</s400><s200><s210>26</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 26gccttgaggc cacggggact agg                                             23</s400><s200><s210>27</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 27gaggccacgg ggactaggac tg                                              22</s400><s200><s210>28</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 28gagtctggct gggaggtgac tg                                              22</s400><s200><s210>29</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 29ggctgggagg tgactgtaca cc                                              22</s400><s200><s210>30</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 30gagtcgcgca gcagggggtg ta                                              22</s400><s200><s210>31</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 31ctccaggagt cgcgcagcag gg                                              22</s400><s200><s210>32</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 32cggttcctcc aggagtcgcg ca                                              22</s400><s200><s210>33</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 33cggttcctcc aggagtcgcg ca                                              22</s400><s200><s210>34</s210><s211>22</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 34gggattcggt tcctccagga gt                                              22</s400><s200><s210>35</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 35ggaaggaaag gctggctccc ggc                                             23</s400><s200><s210>36</s210><s211>23</s211><s212>DNA</s212><s213>Mus musculus</s213></s200><s400> 36gggagtaatg actgtggtgg aat                                             23</s400><s200><s210>37</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 37Arg Ser Asp Asn Leu Ala Arg1               5</s400><s200><s210>38</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 38Thr Pro Ser Tyr Leu Pro Thr1               5</s400><s200><s210>39</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 39Arg Ser Asp His Leu Ser Ala1               5</s400><s200><s210>40</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 40Gln Glu Ser Asp Leu Val Arg1               5</s400><s200><s210>41</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 41Ser Asn Gln Asn Leu Thr Thr1               5</s400><s200><s210>42</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 42Leu Arg His His Leu Thr Arg1               5</s400><s200><s210>43</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 43Arg Ser Ala His Leu Ser Arg1               5</s400><s200><s210>44</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 44Arg Ser Asp Asn Leu Ser Glu1               5</s400><s200><s210>45</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 45Arg Ser Asp Ser Leu Leu Arg1               5</s400><s200><s210>46</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 46Arg Ser Asp Thr Leu Ser Gln1               5</s400><s200><s210>47</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 47Arg Ser Asp Asp Leu Thr Arg1               5</s400><s200><s210>48</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 48Arg Ser Asp Asp Leu Thr Arg1               5</s400><s200><s210>49</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 49Arg Ser Asp His Leu Ser Thr1               5</s400><s200><s210>50</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 50Leu Arg His His Leu Thr Arg1               5</s400><s200><s210>51</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 51Asp Arg Ser Ala Leu Ala Arg1               5</s400><s200><s210>52</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 52Gln Ser Gly Asn Leu Ala Arg1               5</s400><s200><s210>53</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 53Gln Ser Gly Asn Leu Ala Arg1               5</s400><s200><s210>54</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 54Arg Ser Asp His Leu Ser Glu1               5</s400><s200><s210>55</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 55Trp Asn Ser Asp Leu Arg Lys1               5</s400><s200><s210>56</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 56Arg Ser Ala His Leu Ser Arg1               5</s400><s200><s210>57</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 57Gln Ser Ala His Arg Lys Asn1               5</s400><s200><s210>58</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 58Asp Arg Ser His Leu Thr Arg1               5</s400><s200><s210>59</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 59Arg Ser Asp His Leu Ser Arg1               5</s400><s200><s210>60</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 60Asp Arg Ser His Leu Thr Arg1               5</s400><s200><s210>61</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 61Arg Ser Asp Thr Leu Ser Thr1               5</s400><s200><s210>62</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 62Gln Lys Gly Thr Leu Gly Glu1               5</s400><s200><s210>63</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 63Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>64</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 64Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>65</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 65Gln Lys Gly Thr Leu Gly Glu1               5</s400><s200><s210>66</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 66Arg Ser Asp Val Leu Ser Ala1               5</s400><s200><s210>67</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 67Arg Ser Asp Asn Leu Ser Glu1               5</s400><s200><s210>68</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 68Arg Ser Ala Asp Leu Thr Arg1               5</s400><s200><s210>69</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 69Arg Ser Ala Asp Leu Thr Arg1               5</s400><s200><s210>70</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 70Gln Ser Gly His Leu Ala Arg1               5</s400><s200><s210>71</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 71Arg Ser Asp Thr Leu Ser Glu1               5</s400><s200><s210>72</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 72Gln Ser Gly His Leu Ala Arg1               5</s400><s200><s210>73</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 73Asp Asp Ser His Arg Lys Asp1               5</s400><s200><s210>74</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 74Asp Arg Ser Ala Leu Ala Arg1               5</s400><s200><s210>75</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 75Asp Arg Ser Ala Leu Ala Arg1               5</s400><s200><s210>76</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 76Asp Arg Ser Asn Leu Thr Arg1               5</s400><s200><s210>77</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 77Asp Arg Ser His Leu Ala Arg1               5</s400><s200><s210>78</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 78Arg Lys Tyr Tyr Leu Ala Lys1               5</s400><s200><s210>79</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 79Gln Ser Ser Asp Leu Arg Arg1               5</s400><s200><s210>80</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 80Lys Arg Cys Asn Leu Arg Cys1               5</s400><s200><s210>81</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 81Gln Arg Cys His Leu Thr Lys1               5</s400><s200><s210>82</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 82His Asn Ser His Arg Thr Lys1               5</s400><s200><s210>83</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 83Gln Ser Ser Asp Leu Arg Arg1               5</s400><s200><s210>84</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 84Gln Ser Ser Asp Leu Arg Arg1               5</s400><s200><s210>85</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 85Thr Asn Ser Asn Arg Ile Thr1               5</s400><s200><s210>86</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 86Gln Ser Gly Thr Arg Lys Thr1               5</s400><s200><s210>87</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 87Met Ala Cys Cys Arg Tyr Ala1               5</s400><s200><s210>88</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 88Gln Arg Ile Asp Leu Thr Arg1               5</s400><s200><s210>89</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 89Gln Arg Ile Asp Leu Thr Arg1               5</s400><s200><s210>90</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 90Tyr Ser Trp Arg Leu Ser Gln1               5</s400><s200><s210>91</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 91Gln Ser Gly Asn Leu Ala Arg1               5</s400><s200><s210>92</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 92Asp Arg Ser Asp Leu Ser Arg1               5</s400><s200><s210>93</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 93Asp Ser Ser His Arg Thr Arg1               5</s400><s200><s210>94</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 94Gln Ser Gly Asn Leu Ala Arg1               5</s400><s200><s210>95</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 95Asp Arg Ser Ala Arg Asn Ser1               5</s400><s200><s210>96</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 96Asp Arg Ser Asn Leu Thr Arg1               5</s400><s200><s210>97</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 97Asp Arg Ser Ser Arg Ile Lys1               5</s400><s200><s210>98</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 98Gln Ser Gly His Leu Ser Arg1               5</s400><s200><s210>99</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 99Ala Arg Trp Tyr Leu Asp Lys1               5</s400><s200><s210>100</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 100Leu Lys Gln His Leu Thr Arg1               5</s400><s200><s210>101</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 101Trp Arg Ser Ser Leu Thr Ala1               5</s400><s200><s210>102</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 102Arg Asn Asp His Arg Ile Lys1               5</s400><s200><s210>103</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 103Lys Arg Cys Asn Leu Arg Cys1               5</s400><s200><s210>104</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 104Asp Arg Ser Ala Leu Ala Arg1               5</s400><s200><s210>105</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 105Asp Arg Ser Ala Leu Ala Arg1               5</s400><s200><s210>106</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 106Gln Lys Gly Thr Leu Gly Glu1               5</s400><s200><s210>107</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 107His Arg Arg Ser Arg Trp Gly1               5</s400><s200><s210>108</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 108Thr Ser Gly His Leu Ser Arg1               5</s400><s200><s210>109</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 109Arg Ser Asp His Leu Ser Glu1               5</s400><s200><s210>110</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 110Glu Arg Gln Thr Leu Ile Lys1               5</s400><s200><s210>111</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 111His Lys Gln His Arg Asp Ala1               5</s400><s200><s210>112</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 112Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>113</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 113Arg Ser Ala Asp Leu Thr Arg1               5</s400><s200><s210>114</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 114Arg Ser Asp His Leu Ser Glu1               5</s400><s200><s210>115</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 115Arg Ser Asp Asn Leu Ser Asn1               5</s400><s200><s210>116</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 116Asp Arg Ser His Leu Thr Arg1               5</s400><s200><s210>117</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 117Arg Ser Asp Thr Leu Ser Gln1               5</s400><s200><s210>118</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 118Arg Ser Asp His Leu Ser Arg1               5</s400><s200><s210>119</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 119Asp Arg Ser His Leu Thr Arg1               5</s400><s200><s210>120</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 120Asp Arg Ser His Leu Thr Arg1               5</s400><s200><s210>121</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 121Gln Ser Gly Asp Leu Thr Arg1               5</s400><s200><s210>122</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 122Arg Ser Asp Val Leu Ser Lys1               5</s400><s200><s210>123</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 123Asp Arg Ser Asp Leu Ser Arg1               5</s400><s200><s210>124</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 124Arg Ser Ala Asp Leu Thr Arg1               5</s400><s200><s210>125</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 125Arg Ser Ala Asp Leu Thr Arg1               5</s400><s200><s210>126</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 126Leu Arg His His Leu Thr Arg1               5</s400><s200><s210>127</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 127Gln Ser Ser Asp Leu Ser Arg1               5</s400><s200><s210>128</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 128Gln Ser Ser Asn Leu Ala Arg1               5</s400><s200><s210>129</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 129Asp Arg Ser His Leu Thr Arg1               5</s400><s200><s210>130</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 130Asp Arg Ser Asp Leu Ser Arg1               5</s400><s200><s210>131</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 131Gln Gln Ser Asp Leu Arg Val1               5</s400><s200><s210>132</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 132Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>133</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 133Arg Ser Asp Asn Leu Ala Arg1               5</s400><s200><s210>134</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 134Arg Ser Asp Thr Leu Ser Thr1               5</s400><s200><s210>135</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 135Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>136</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 136Gln Ser Gly His Leu Ala Arg1               5</s400><s200><s210>137</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 137Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>138</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 138Arg Ser Asp Asn Leu Ser Glu1               5</s400><s200><s210>139</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 139Arg Ser Ala Asp Leu Thr Arg1               5</s400><s200><s210>140</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 140Gln Ser Gly His Leu Ala Arg1               5</s400><s200><s210>141</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 141Gln Ser Gly His Leu Ala Arg1               5</s400><s200><s210>142</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 142Ile Arg Ser Thr Leu Arg Asp1               5</s400><s200><s210>143</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 143Arg Ser Asp Val Leu Ser Glu1               5</s400><s200><s210>144</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 144Trp Arg Ser Cys Arg Ser Ala1               5</s400><s200><s210>145</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 145Gln Ser Ala Asn Arg Thr Lys1               5</s400><s200><s210>146</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 146Gln Ser Gly His Leu Ser Arg1               5</s400><s200><s210>147</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 147Arg Ser Ala Asn Leu Thr Arg1               5</s400><s200><s210>148</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 148His Asn Ser Ser Leu Lys Asp1               5</s400><s200><s210>149</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 149Arg Ser Asp Asp Leu Thr Arg1               5</s400><s200><s210>150</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 150Arg Asn Arg Asp Arg Ile Thr1               5</s400><s200><s210>151</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 151Thr Ser Ser Ser Arg Ile Asn1               5</s400><s200><s210>152</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 152Asp Arg Ser Ala Leu Ala Arg1               5</s400><s200><s210>153</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 153His Asn Ser His Arg Thr Lys1               5</s400><s200><s210>154</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 154Gln Ser Ser Asp Leu Arg Arg1               5</s400><s200><s210>155</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 155Arg Leu Asp Trp Leu Pro Met1               5</s400><s200><s210>156</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 156Arg Leu Asp Trp Leu Pro Met1               5</s400><s200><s210>157</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 157Arg Arg Ala Asp Leu Ser Arg1               5</s400><s200><s210>158</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 158Arg Ser Asp Asp Arg Ile Lys1               5</s400><s200><s210>159</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 159Arg Arg Thr Asp Leu Arg Arg1               5</s400><s200><s210>160</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 160Gln Ser Gly Asp Leu Thr Arg1               5</s400><s200><s210>161</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 161Gln Ser Gly Asp Leu Thr Arg1               5</s400><s200><s210>162</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 162Gln Ser Gly Thr Arg Lys Thr1               5</s400><s200><s210>163</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 163His Arg Ser Thr Arg Asn Arg1               5</s400><s200><s210>164</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 164Gln Ser Ser Asp Leu Arg Arg1               5</s400><s200><s210>165</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 165Asp Arg Ser Asn Leu Thr Arg1               5</s400><s200><s210>166</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 166Asp Arg Ser Asn Leu Thr Arg1               5</s400><s200><s210>167</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 167Arg Ser Ala Asp Leu Ser Arg1               5</s400><s200><s210>168</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 168His Lys Trp Leu Arg Asn Gln1               5</s400><s200><s210>169</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 169His Lys Ser Thr Leu Ser Asp1               5</s400><s200><s210>170</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 170Asp Arg Ser Ser Arg Ile Lys1               5</s400><s200><s210>171</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 171Asp Arg Ser His Leu Ala Arg1               5</s400><s200><s210>172</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 172Arg Lys Trp Thr Leu Gln Gly1               5</s400><s200><s210>173</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 173Leu Lys Gln His Leu Thr Arg1               5</s400><s200><s210>174</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 174Lys Arg Cys Asn Leu Arg Cys1               5</s400><s200><s210>175</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 175Asp Arg Ser Ala Leu Ala Arg1               5</s400><s200><s210>176</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 176Gln Lys Gly Thr Leu Gly Glu1               5</s400><s200><s210>177</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 177Gln Lys Gly Thr Leu Gly Glu1               5</s400><s200><s210>178</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 178His Arg Ser Ser Leu Arg Arg1               5</s400><s200><s210>179</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 179Arg Asn Gln His Arg Lys Thr1               5</s400><s200><s210>180</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 180Asp Arg Ser Asn Leu Thr Arg1               5</s400><s200><s210>181</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 181Asp Asn His Asp Leu Ile Arg1               5</s400><s200><s210>182</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 182Ala Arg Ser Thr Arg Ile Thr1               5</s400><s200><s210>183</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 183Gln Ser Ser Asp Leu Ser Arg1               5</s400><s200><s210>184</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 184Asp Ser Ser Thr Arg Lys Thr1               5</s400><s200><s210>185</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 185Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>186</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 186Gln Gln Ser Asp Leu Arg Val1               5</s400><s200><s210>187</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 187Arg Ser Asp Ser Leu Leu Arg1               5</s400><s200><s210>188</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 188Thr Ser Gly Ser Leu Ser Arg1               5</s400><s200><s210>189</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 189Arg Ser Asp His Leu Ser Arg1               5</s400><s200><s210>190</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 190Ile Asp His Gly Arg Tyr Arg1               5</s400><s200><s210>191</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 191Thr Ser Gly Asn Leu Thr Arg1               5</s400><s200><s210>192</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 192Thr Ser Gly Asn Leu Thr Arg1               5</s400><s200><s210>193</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 193Gln Ser Ser Asp Leu Ser Arg1               5</s400><s200><s210>194</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 194Gln Ser Gly Asp Leu Thr Arg1               5</s400><s200><s210>195</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 195Ser Glu Ala Asp Arg Ser Arg1               5</s400><s200><s210>196</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 196Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>197</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 197Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>198</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 198Arg Ser Asp Val Leu Ser Lys1               5</s400><s200><s210>199</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 199Arg Ser Asp Asp Leu Ser Arg1               5</s400><s200><s210>200</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 200Asp Arg Ser His Leu Thr Arg1               5</s400><s200><s210>201</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 201Asp Arg Ser Asn Leu Ser Arg1               5</s400><s200><s210>202</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 202Gln Ser Ser Asp Leu Ser Arg1               5</s400><s200><s210>203</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 203Asp Arg Ser Asn Arg Thr Thr1               5</s400><s200><s210>204</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 204Arg Ser Asp Asn Leu Ala Arg1               5</s400><s200><s210>205</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 205Arg Ser Ala His Leu Ser Arg1               5</s400><s200><s210>206</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 206Arg Ser Asp Asn Leu Ala Arg1               5</s400><s200><s210>207</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 207Tyr Asp Tyr Gly Arg Tyr Thr1               5</s400><s200><s210>208</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 208Arg Trp Gln Tyr Leu Pro Thr1               5</s400><s200><s210>209</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 209Gln Ser Gly His Leu Ala Arg1               5</s400><s200><s210>210</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 210Arg Ser Ala Asp Leu Thr Arg1               5</s400><s200><s210>211</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 211Gln Ser Gly His Leu Ala Arg1               5</s400><s200><s210>212</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 212Ile Arg Ser Thr Leu Arg Asp1               5</s400><s200><s210>213</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 213Ile Arg Ser Thr Leu Arg Asp1               5</s400><s200><s210>214</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 214Arg Arg Glu Asp Leu Ile Thr1               5</s400><s200><s210>215</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 215Gln Ser Gly Asn Leu Ala Arg1               5</s400><s200><s210>216</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 216Gln Ser Ala Asn Arg Thr Lys1               5</s400><s200><s210>217</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 217Thr Ser Gly Ser Leu Thr Arg1               5</s400><s200><s210>218</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 218Leu Arg His His Leu Thr Arg1               5</s400><s200><s210>219</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 219Tyr Lys Trp Thr Leu Arg Asn1               5</s400><s200><s210>220</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 220Gln Ser Ala Thr Arg Thr Lys1               5</s400><s200><s210>221</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 221Trp Lys Glu Ser Leu Gly Ala1               5</s400><s200><s210>222</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 222Arg Ser Ala Asp Leu Ser Arg1               5</s400><s200><s210>223</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 223Gln Arg Cys His Leu Thr Lys1               5</s400><s200><s210>224</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 224Asn Ser Arg Asn Leu Arg Asn1               5</s400><s200><s210>225</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 225Gln Ser Ser Asp Leu Arg Arg1               5</s400><s200><s210>226</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 226Asp Arg Ser Asn Leu Thr Arg1               5</s400><s200><s210>227</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 227Asp Leu Thr Thr Leu Arg Lys1               5</s400><s200><s210>228</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 228Asp Leu Thr Thr Leu Arg Lys1               5</s400><s200><s210>229</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 229Asp Arg Ser His Leu Ala Arg1               5</s400><s200><s210>230</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 230Asp Thr Gly Ala Arg Leu Lys1               5</s400><s200><s210>231</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 231Asp Arg Ser Asn Leu Thr Arg1               5</s400><s200><s210>232</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 232Val Ala Glu Tyr Arg Tyr Lys1               5</s400><s200><s210>233</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 233Val Ala Glu Tyr Arg Tyr Lys1               5</s400><s200><s210>234</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 234Arg Ser Asp Asp Arg Ile Lys1               5</s400><s200><s210>235</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 235Gln Ser Ala Asn Arg Thr Lys1               5</s400><s200><s210>236</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 236Gln Ser Ser Asp Leu Arg Arg1               5</s400><s200><s210>237</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 237His Lys Trp Leu Arg Asn Gln1               5</s400><s200><s210>238</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 238Gln Ser Thr His Arg Asn Ala1               5</s400><s200><s210>239</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 239His Arg Ser Ser Leu Arg Arg1               5</s400><s200><s210>240</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 240Asp Arg Ser Val Leu His Arg1               5</s400><s200><s210>241</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 241Arg Ser Asp Asp Arg Lys Thr1               5</s400><s200><s210>242</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 242His Lys Ser Thr Leu Ser Asp1               5</s400><s200><s210>243</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 243Asp Arg Ser His Leu Ala Arg1               5</s400><s200><s210>244</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 244Asp Arg Ser Ala Leu Ala Arg1               5</s400><s200><s210>245</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 245Arg Lys Trp Thr Leu Gln Gly1               5</s400><s200><s210>246</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 246Asp Arg Ser Ala Leu Ala Arg1               5</s400><s200><s210>247</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 247Gln Lys Gly Thr Leu Gly Glu1               5</s400><s200><s210>248</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 248His Arg Ser Ser Leu Arg Arg1               5</s400><s200><s210>249</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 249His Arg Ser Ser Leu Arg Arg1               5</s400><s200><s210>250</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 250Thr Ser Ser Asn Leu Ser Arg1               5</s400><s200><s210>251</s210><s211>20</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220><s220><s221>SITE</s221><s222>(1)..(20)</s222><s223>/note=&#x201c;This sequence may encompass 1-4 &#x2018;Gly Gly      Gly Gly Ser&#x2019; repeating units&#x201d;</s223></s220><s220><s221>source</s221><s223>/note=&#x201c;See specification as filed for detailed      description of substitutions and preferred embodiments&#x201d;</s223></s220></s200><s400> 251Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser            20</s400><s200><s210>252</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 252Asp Gly Gly Gly Ser1               5</s400><s200><s210>253</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 253Thr Gly Glu Lys Pro1               5</s400><s200><s210>254</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 254Leu Arg Gln Lys Asp Gly Glu Arg Pro1               5</s400><s200><s210>255</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 255Gly Gly Arg Arg1</s400><s200><s210>256</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 256Gly Gly Arg Arg Gly Gly Gly Ser1               5</s400><s200><s210>257</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 257Leu Arg Gln Arg Asp Gly Glu Arg Pro1               5</s400><s200><s210>258</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 258Leu Arg Gln Lys Asp Gly Gly Gly Ser Glu Arg Pro1               5                   10</s400><s200><s210>259</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 259Leu Arg Gln Lys Asp Gly Gly Gly Ser Gly Gly Gly Ser Glu Arg Pro1               5                   10                  15</s400><s200><s210>260</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 260Thr Gly Ser Gln Lys Pro1               5</s400><s200><s210>261</s210><s211>96</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 261Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu Val Thr Phe Lys1               5                   10                  15Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys Leu Leu Asp Thr            20                  25                  30Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu Asn Tyr Lys Asn        35                  40                  45Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp Val Ile Leu Arg    50                  55                  60Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg Glu Ile His Gln65                  70                  75                  80Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile Lys Ser Ser Val                85                  90                  95</s400><s200><s210>262</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 262Arg Ser Ala Asn Leu Thr Arg1               5</s400><s200><s210>263</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 263Arg Gln Glu His Arg Val Ala1               5</s400><s200><s210>264</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 264Gln Ser Ala Asp Arg Thr Lys1               5</s400><s200><s210>265</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 265Asp Arg Ser Asn Arg Lys Thr1               5</s400><s200><s210>266</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 266Arg Asn Gly His Leu Leu Asp1               5</s400><s200><s210>267</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 267Trp Arg Ser Ser Leu Arg Ala1               5</s400><s200><s210>268</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 268Ile Lys His Asp Leu His Arg1               5</s400><s200><s210>269</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 269Asp Arg Ser Tyr Arg Asn Thr1               5</s400><s200><s210>270</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 270Tyr Arg Trp Leu Arg Asn Asn1               5</s400><s200><s210>271</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 271Gln Asn Ala Asn Leu Met Lys1               5</s400><s200><s210>272</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 272Arg Arg Ser Asp Leu Lys Arg1               5</s400><s200><s210>273</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 273Ala Lys Trp Asn Leu Asp Ala1               5</s400><s200><s210>274</s210><s211>19</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 274tatgtaacgg ggagctgga                                                  19</s400><s200><s210>275</s210><s211>23</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 275atgagccacg tcagggagcg atg                                             23</s400><s200><s210>276</s210><s211>22</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 276cacttgcatc agttgatacc gc                                              22</s400><s200><s210>277</s210><s211>23</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 277tttaagttaa agggtgcagc gct                                             23</s400><s200><s210>278</s210><s211>22</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 278cggcgctcgc gggcggaggt cg                                              22</s400><s200><s210>279</s210><s211>22</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 279acgcggggcg gggaagggaa gc                                              22</s400><s200><s210>280</s210><s211>23</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 280gcctcggtcg tgaggagagg aga                                             23</s400><s200><s210>281</s210><s211>22</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 281tgtaacgggg agctggagct tt                                              22</s400><s200><s210>282</s210><s211>22</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 282gggccgggaa tgagtcaccg ga                                              22</s400><s200><s210>283</s210><s211>22</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 283cctccgagcc agtcgctgac ag                                              22</s400><s200><s210>284</s210><s211>23</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 284ccgagccagt cgctgacagc cgc                                             23</s400><s200><s210>285</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 285Tyr Lys Cys Cys Leu Ser Asp1               5</s400><s200><s210>286</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 286Tyr Pro Lys Asp Leu Ala Arg1               5</s400><s200><s210>287</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 287Lys His Ser Thr Arg Arg Val1               5</s400><s200><s210>288</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 288Arg Ser Asp Ala Leu Ser Glu1               5</s400><s200><s210>289</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 289Gln Leu Thr His Leu Asn Ser1               5</s400><s200><s210>290</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 290Arg Ser Ser Asp Arg Thr Lys1               5</s400><s200><s210>291</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 291Leu Arg Gln Asp Leu Lys Arg1               5</s400><s200><s210>292</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 292Gln Ser Ser Thr Arg Ala Arg1               5</s400><s200><s210>293</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 293Arg Ser Ala Asn Leu Ala Arg1               5</s400><s200><s210>294</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 294Asp Arg Ser Ala Leu Ser Arg1               5</s400><s200><s210>295</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 295Met Arg His His Leu Asp Asp1               5</s400><s200><s210>296</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 296Gln Lys Gly His Leu Arg Lys1               5</s400><s200><s210>297</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 297Thr Asn Gln Asn Arg Ile Thr1               5</s400><s200><s210>298</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 298Asp Ser Ser Asp Arg Lys Lys1               5</s400><s200><s210>299</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 299Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp Asn Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Asp Ser His Arg Lys    50                  55                  60Asp His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Ser Glu His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Ser Ala Asn Arg Thr Lys His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Asp Asn His Asp Leu Ile Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Thr Ser Gly Ser                165                 170                 175Leu Thr Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>300</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 300Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Thr Pro            20                  25                  30Ser Tyr Leu Pro Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ala Leu Ala    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Glu Arg Gln Thr Leu Ile Lys His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Thr Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Ser Gly His Leu Ser Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Ala Arg Ser Thr Arg Ile Thr His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Leu Arg His His                165                 170                 175Leu Thr Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>301</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 301Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser            20                  25                  30Asp His Leu Ser Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ala Leu Ala    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser His Lys Gln His Arg                85                  90                  95Asp Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Arg Ser Ala Asn Leu Thr Arg His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Gln Ser Ser Asp Leu Ser Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Tyr Lys Trp Thr Leu Arg Asn His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>302</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 302Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Glu            20                  25                  30Ser Asp Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Asn Leu Thr    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Asp Arg Ser Asn Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala His Asn Ser Ser Leu Lys Asp His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Asp Ser Ser Thr Arg Lys Thr His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Ala Thr                165                 170                 175Arg Thr Lys His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>303</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 303Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Ser Asn            20                  25                  30Gln Asn Leu Thr Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser His Leu Ala    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Ala Asp Leu                85                  90                  95Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asp Leu Thr Arg His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Arg Asn Phe Ser Asp Arg Ser Asn Leu Ser Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Trp Lys Glu Ser Leu Gly Ala His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>304</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 304Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Leu Arg            20                  25                  30His His Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Lys Tyr Tyr Leu Ala    50                  55                  60Lys His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Ser Glu His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Arg Asn Arg Asp Arg Ile Thr His Thr Lys Ile His Thr        115                 120                 125His Pro Arg Ala Pro Ile Pro Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Arg Asn Phe Ser Gln Gln Ser Asp Leu Arg Val His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Arg Ser Ala Asp Leu Ser Arg His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>305</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 305Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser            20                  25                  30Ala His Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Asp Leu Arg    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser Asp Asn Leu                85                  90                  95Ser Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Thr Ser Ser Ser Arg Ile Asn His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Arg Ser Asp Ser Leu Leu Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Gln Arg Cys His Leu Thr Lys His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>306</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 306Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp Asn Leu Ser Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Lys Arg Cys Asn Leu Arg    50                  55                  60Cys His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Arg Ser His Leu                85                  90                  95Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ala Leu Ala Arg His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Arg Asn Phe Ser Thr Ser Gly Ser Leu Ser Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Asn Ser Arg Asn Leu Arg Asn His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>307</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 307Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser            20                  25                  30Asp Ser Leu Leu Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Arg Cys His Leu Thr    50                  55                  60Lys His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Arg Ser Asp Thr Leu Ser Gln His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala His Asn Ser His Arg Thr Lys His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Arg Ser Asp His Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Asp                165                 170                 175Leu Arg Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>308</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 308Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser            20                  25                  30Asp Thr Leu Ser Gln His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His Asn Ser His Arg Thr    50                  55                  60Lys His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Arg Ser Asp His Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Ser Ser Asp Leu Arg Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Ile Asp His Gly Arg Tyr Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Asn                165                 170                 175Leu Thr Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>309</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 309Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp Asp Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Asp Leu Arg    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Asp Arg Ser His Leu Thr Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Arg Leu Asp Trp Leu Pro Met His Thr Lys Ile His Thr        115                 120                 125His Pro Arg Ala Pro Ile Pro Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Arg Asn Phe Ser Thr Ser Gly Asn Leu Thr Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Asp Leu Thr Thr Leu Arg Lys His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>310</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 310Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser            20                  25                  30Gly Asn Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Leu Ser Gln Asp Leu Asn    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Arg Ser Ala Leu                85                  90                  95Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Arg Asn Asp Asp Arg Lys Lys His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Arg Asn Phe Ser Gln Ser Gly Asn Leu Ala Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Gln Arg Ile Asp Leu Thr Arg His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>311</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 311Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp His Leu Ser Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Thr Asn Ser Asn Arg Ile    50                  55                  60Thr His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Gln Ser Gly Asp Leu Thr Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Arg Arg Ala Asp Leu Ser Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Gln Ser Ser Asp Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser His                165                 170                 175Leu Ala Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>312</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 312Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Leu Arg            20                  25                  30His His Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly Thr Arg Lys    50                  55                  60Thr His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Arg Ser Asp Val Leu Ser Lys His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Arg Ser Asp Asp Arg Ile Lys His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Gln Ser Gly Asp Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Thr Gly Ala                165                 170                 175Arg Leu Lys His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>313</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 313Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Arg            20                  25                  30Ser Ala Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Met Ala Cys Cys Arg Tyr    50                  55                  60Ala His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Asp Arg Ser Asp Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Arg Arg Thr Asp Leu Arg Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Ser Glu Ala Asp Arg Ser Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Asn                165                 170                 175Leu Thr Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>314</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 314Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser            20                  25                  30Gly Asn Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Arg Ile Asp Leu Thr    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Ala Asp Leu                85                  90                  95Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly Asp Leu Thr Arg His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Arg Asn Phe Ser Asp Arg Ser Asn Leu Ser Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Val Ala Glu Tyr Arg Tyr Lys His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>315</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 315Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Gln Ser            20                  25                  30Gly Asn Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Arg Ile Asp Leu Thr    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser Ala Asp Leu                85                  90                  95Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly Asp Leu Thr Arg His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Asp Arg Ser Asn Leu Ser Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Val Ala Glu Tyr Arg Tyr Lys His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>316</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 316Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp His Leu Ser Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Tyr Ser Trp Arg Leu Ser    50                  55                  60Gln His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Leu Arg His His Leu Thr Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Ser Gly Thr Arg Lys Thr His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Arg Ser Asp Val Leu Ser Lys His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asp                165                 170                 175Arg Ile Lys His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>317</s210><s211>299</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 317Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Trp Asn            20                  25                  30Ser Asp Leu Arg Lys His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly Asn Leu Ala    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Gln Ser Ser Asp Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala His Arg Ser Thr Arg Asn Arg His Thr Lys Ile His Thr        115                 120                 125His Pro Arg Ala Pro Ile Pro Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Arg Ser Asp Asp Leu Ser Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Gln Ser Ala Asn Arg Thr Lys His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser Glu    290                 295</s400><s200><s210>318</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 318Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser            20                  25                  30Ala His Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Asp Leu Ser    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Gln Ser Ser Asn Leu Ala Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Ser Ser Asp Leu Arg Arg His Thr Lys Ile His Thr        115                 120                 125His Pro Arg Ala Pro Ile Pro Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Asp Arg Ser His Leu Thr Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Gln Ser Ser Asp Leu Arg Arg His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>319</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 319Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Gln Ser            20                  25                  30Ala His Arg Lys Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Ser Ser His Arg Thr    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Asp Arg Ser His Leu                85                  90                  95Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Asn Leu Thr Arg His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Asp Arg Ser Asn Leu Ser Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175His Lys Trp Leu Arg Asn Gln His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>320</s210><s211>302</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 320Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Asp Arg            20                  25                  30Ser His Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly Asn Leu Ala    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Asp Arg Ser Asp Leu                85                  90                  95Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Asn Leu Thr Arg His Thr        115                 120                 125Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro Phe Gln Cys    130                 135                 140Arg Ile Cys Met Gln Asn Phe Ser Gln Ser Ser Asp Leu Ser Arg His145                 150                 155                 160Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly                165                 170                 175Arg Lys Phe Ala Gln Ser Thr His Arg Asn Ala His Thr Lys Ile His            180                 185                 190Leu Arg Gln Lys Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser        195                 200                 205Leu Thr Ala Trp Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val    210                 215                 220Asp Phe Thr Arg Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile225                 230                 235                 240Val Tyr Arg Asn Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu                245                 250                 255Gly Tyr Gln Leu Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly            260                 265                 270Glu Glu Pro Trp Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro        275                 280                 285Asp Ser Glu Thr Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295                 300</s400><s200><s210>321</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 321Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp His Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ala Arg Asn    50                  55                  60Ser His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Gln Gln Ser Asp Leu Arg Val His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Arg Ser Ala Asp Leu Ser Arg His Thr Lys Ile His Thr        115                 120                 125His Pro Arg Ala Pro Ile Pro Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Arg Asn Phe Ser Asp Arg Ser Asn Arg Thr Thr His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175His Arg Ser Ser Leu Arg Arg His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>322</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 322Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Asp Arg            20                  25                  30Ser His Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Asn Leu Thr    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Asp Arg Ser Asn Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala His Lys Trp Leu Arg Asn Gln His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Arg Ser Asp Asn Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Val                165                 170                 175Leu His Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>323</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 323Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser            20                  25                  30Asp Thr Leu Ser Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ser Arg Ile    50                  55                  60Lys His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Arg Ser Asp Asn Leu Ala Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala His Lys Ser Thr Leu Ser Asp His Thr Lys Ile His Thr        115                 120                 125His Pro Arg Ala Pro Ile Pro Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Arg Ser Ala His Leu Ser Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Arg Ser Asp Asp Arg Lys Thr His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>324</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 324Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Gln Lys            20                  25                  30Gly Thr Leu Gly Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly His Leu Ser    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser Asp Thr Leu                85                  90                  95Ser Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ser Arg Ile Lys His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Arg Ser Asp Asn Leu Ala Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175His Lys Ser Thr Leu Ser Asp His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>325</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 325Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Arg            20                  25                  30Ser Asn Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Ala Arg Trp Tyr Leu Asp    50                  55                  60Lys His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Asp Arg Ser Asn Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Asp Arg Ser His Leu Ala Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Tyr Asp Tyr Gly Arg Tyr Thr His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser His                165                 170                 175Leu Ala Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>326</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 326Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Asp Arg            20                  25                  30Ser Asn Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Leu Lys Gln His Leu Thr    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Gln Ser Gly His Leu Ala Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Arg Lys Trp Thr Leu Gln Gly His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Arg Trp Gln Tyr Leu Pro Thr His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ala                165                 170                 175Leu Ala Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>327</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 327Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Gln Lys            20                  25                  30Gly Thr Leu Gly Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Trp Arg Ser Ser Leu Thr    50                  55                  60Ala His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Asp Arg Ser Asn Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Leu Lys Gln His Leu Thr Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Gln Ser Gly His Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Lys Trp Thr                165                 170                 175Leu Gln Gly His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>328</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 328Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp Val Leu Ser Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Lys Lys Phe Ala Arg Asn Asp His Arg Ile    50                  55                  60Lys His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Arg Ser Asp Asn Leu Ser Glu His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Lys Arg Cys Asn Leu Arg Cys His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Arg Ser Ala Asp Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ala                165                 170                 175Leu Ala Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>329</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 329Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp Asn Leu Ser Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Lys Arg Cys Asn Leu Arg    50                  55                  60Cys His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Arg Ser Ala Asp Leu Thr Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Asp Arg Ser Ala Leu Ala Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Gln Ser Gly His Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Lys Gly Thr                165                 170                 175Leu Gly Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>330</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 330Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Ala Asp Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ala Leu Ala    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Gln Ser Gly His Leu Ala Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Lys Gly Thr Leu Gly Glu His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Ile Arg Ser Thr Leu Arg Asp His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His Arg Ser Ser                165                 170                 175Leu Arg Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>331</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 331Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser            20                  25                  30Ala Asp Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ala Leu Ala    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Gln Ser Gly His Leu Ala Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Lys Gly Thr Leu Gly Glu His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Ile Arg Ser Thr Leu Arg Asp His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His Arg Ser Ser                165                 170                 175Leu Arg Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>332</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 332Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Gln Ser            20                  25                  30Gly His Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Lys Gly Thr Leu Gly    50                  55                  60Glu His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Ile Arg Ser Thr Leu Arg Asp His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala His Arg Ser Ser Leu Arg Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Arg Arg Glu Asp Leu Ile Thr His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Thr Ser Ser Asn                165                 170                 175Leu Ser Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>333</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 333Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser            20                  25                  30Asp Thr Leu Ser Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His Arg Arg Ser Arg Trp    50                  55                  60Gly His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser Asp Val Leu                85                  90                  95Ser Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Arg Asn Gln His Arg Lys Thr His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Gln Ser Gly Asn Leu Ala Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Ala Lys Trp Asn Leu Asp Ala His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>334</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 334Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Gln Ser            20                  25                  30Gly His Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Thr Ser Gly His Leu Ser    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Trp Arg Ser Cys Arg Ser Ala His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Asp Arg Ser Asn Leu Thr Arg His Thr Lys Ile His Thr        115                 120                 125His Pro Arg Ala Pro Ile Pro Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Gln Ser Ala Asn Arg Thr Lys His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Thr Ser Ser Asn Leu Ser Arg His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>335</s210><s211>265</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 335Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp Val Leu Ser Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Lys His Ser Thr Arg Arg    50                  55                  60Val His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Lys Phe Ala Arg Ser Asp His Leu Ser Arg His Thr                85                  90                  95Lys Ile His Thr Gly Glu Lys Pro Phe Gln Cys Arg Ile Cys Met Arg            100                 105                 110Asn Phe Ser Asp Arg Ser Asn Leu Ser Arg His Ile Arg Thr His Thr        115                 120                 125Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Trp    130                 135                 140Arg Ser Ser Leu Arg Ala His Thr Lys Ile His Leu Arg Gln Lys Asp145                 150                 155                 160Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser                165                 170                 175Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu            180                 185                 190Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val        195                 200                 205Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr    210                 215                 220Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu225                 230                 235                 240Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala                245                 250                 255Phe Glu Ile Lys Ser Ser Val Arg Ser            260                 265</s400><s200><s210>336</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 336Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Tyr Lys            20                  25                  30Cys Cys Leu Ser Asp His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Ala Asn Leu Thr    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Arg Ser Asp His Leu Ser Ala His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Asp Arg Ser Ala Leu Ala Arg His Thr Lys Ile His Thr        115                 120                 125His Pro Arg Ala Pro Ile Pro Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Ile Lys His Asp Leu His Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Arg Ser Ala Asn Leu Thr Arg His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>337</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 337Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Tyr Pro            20                  25                  30Lys Asp Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Thr Ser Gly Asn Leu Thr    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Thr Ser Gly Ser Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Ser Ala Asp Arg Thr Lys His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Gln Ser Gly Asp Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Tyr Arg Trp Leu                165                 170                 175Arg Asn Asn His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>338</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 338Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser            20                  25                  30Ala Asp Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly Asp Leu Thr    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser Asp His Leu                85                  90                  95Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Asn Arg Lys Thr His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Thr Ser Gly Ser Leu Ser Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Gln Asn Ala Asn Leu Met Lys His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>339</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 339Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser            20                  25                  30Gly His Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly His Leu Ser    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Asp Arg Ser His Leu Thr Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Ser Ser Asp Leu Arg Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Asp Arg Ser Tyr Arg Asn Thr His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Arg Ser Asp                165                 170                 175Leu Lys Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>340</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 340Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser            20                  25                  30Gly Asn Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Gln Glu His Arg Val    50                  55                  60Ala His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Gln Ser Gly His Leu Ala Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Arg Asn Gly His Leu Leu Asp His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Arg Ser Ala His Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Asp                165                 170                 175Leu Arg Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>341</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 341Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Gln Ser            20                  25                  30Gly His Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Leu Thr His Leu Asn    50                  55                  60Ser His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Arg Ser Asp Asn Leu                85                  90                  95Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Met Arg His His Leu Asp Asp His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Gln Asn Phe Ser Leu Arg His His Leu Thr Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Asp Arg Ser Tyr Arg Asn Thr His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>342</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 342Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Gln Ser            20                  25                  30Ser Asp Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly His Leu Ser    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Gln Ser Ser Asp Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Lys Gly His Leu Arg Lys His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Arg Ser Asp His Leu Ser Glu His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Ala Asn                165                 170                 175Arg Thr Lys His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>343</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 343Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser            20                  25                  30Asp Ala Leu Ser Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Ser Asp Arg Thr    50                  55                  60Lys His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Arg Asn Phe Ser Arg Ser Ala Asn Leu Ala Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Thr Asn Gln Asn Arg Ile Thr His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser    130                 135                 140Arg Ser Ala His Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Asp                165                 170                 175Leu Ser Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>344</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 344Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Gln Ser            20                  25                  30Gly Asn Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Gln Glu His Arg Val    50                  55                  60Ala His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Gln Ser Gly His Leu Ala Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Arg Asn Gly His Leu Leu Asp His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Arg Ser Ala His Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Asp                165                 170                 175Leu Arg Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>345</s210><s211>294</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 345Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser Asp Arg            20                  25                  30Ser Asn Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Leu Arg Gln Asp Leu Lys    50                  55                  60Arg His Thr Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg65                  70                  75                  80Ile Cys Met Gln Asn Phe Ser Asp Arg Ser Ala Leu Ser Arg His Ile                85                  90                  95Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg            100                 105                 110Lys Phe Ala Gln Ser Gly Asp Leu Thr Arg His Thr Lys Ile His Thr        115                 120                 125Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Gln Asn Phe Ser    130                 135                 140Arg Ser Ala Asn Leu Ala Arg His Ile Arg Thr His Thr Gly Glu Lys145                 150                 155                 160Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Asp Ser Ser Asp                165                 170                 175Arg Lys Lys His Thr Lys Ile His Leu Arg Gln Lys Asp Ala Ala Arg            180                 185                 190Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp Ser Arg Thr Leu        195                 200                 205Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg Glu Glu Trp Lys    210                 215                 220Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn Val Met Leu Glu225                 230                 235                 240Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu Thr Lys Pro Asp                245                 250                 255Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp Leu Val Glu Arg            260                 265                 270Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr Ala Phe Glu Ile        275                 280                 285Lys Ser Ser Val Arg Ser    290</s400><s200><s210>346</s210><s211>298</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 346Met Ala Pro Lys Lys Lys Arg Lys Val Gly Val Pro Ala Ala Met Ala1               5                   10                  15Glu Arg Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Arg            20                  25                  30Ser Asp Leu Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe        35                  40                  45Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Thr Arg Ala    50                  55                  60Arg His Thr Lys Ile His Thr His Pro Arg Ala Pro Ile Pro Lys Pro65                  70                  75                  80Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Asp Leu                85                  90                  95Ser Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp            100                 105                 110Ile Cys Gly Arg Lys Phe Ala Asp Arg Ser Ala Leu Ala Arg His Thr        115                 120                 125Lys Ile His Thr Gly Ser Gln Lys Pro Phe Gln Cys Arg Ile Cys Met    130                 135                 140Arg Asn Phe Ser Ile Lys His Asp Leu His Arg His Ile Arg Thr His145                 150                 155                 160Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala                165                 170                 175Arg Ser Ala Asn Leu Thr Arg His Thr Lys Ile His Leu Arg Gln Lys            180                 185                 190Asp Ala Ala Arg Gly Ser Gly Gly Asp Ala Lys Ser Leu Thr Ala Trp        195                 200                 205Ser Arg Thr Leu Val Thr Phe Lys Asp Val Phe Val Asp Phe Thr Arg    210                 215                 220Glu Glu Trp Lys Leu Leu Asp Thr Ala Gln Gln Ile Val Tyr Arg Asn225                 230                 235                 240Val Met Leu Glu Asn Tyr Lys Asn Leu Val Ser Leu Gly Tyr Gln Leu                245                 250                 255Thr Lys Pro Asp Val Ile Leu Arg Leu Glu Lys Gly Glu Glu Pro Trp            260                 265                 270Leu Val Glu Arg Glu Ile His Gln Glu Thr His Pro Asp Ser Glu Thr        275                 280                 285Ala Phe Glu Ile Lys Ser Ser Val Arg Ser    290                 295</s400><s200><s210>347</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 347Gly Gly Gly Gly Ser1               5</s400><s200><s210>348</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 348Thr Gly Glu Lys Pro Phe Ala1               5</s400><s200><s210>349</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 349Thr Gly Ser Gln Lys Pro Phe Gln1               5</s400><s200><s210>350</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 350Leu Arg Gln Lys Asp Ala Ala Arg Gly Ser Gly Gly1               5                   10</s400><s200><s210>351</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 351Leu Arg Gly Ser Gly Gly1               5</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002460A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002460</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17779932</doc-number><date>20201125</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>KR</country><doc-number>10-2019-0153680</doc-number><date>20191126</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>475</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>63</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>475</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>63</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2319</main-group><subgroup>30</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e61">LONG-ACTING GDF15 FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>YUHAN CORPORATION</orgname><address><city>Seoul</city><country>KR</country></address></addressbook><residence><country>KR</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>LIM</last-name><first-name>Seyoung</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>PARK</last-name><first-name>Young Bong</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>KIM</last-name><first-name>Sukyung</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>SIM</last-name><first-name>Bo Ra</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>CHONG</last-name><first-name>Wonee</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>CHOI</last-name><first-name>Hyun Ho</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>YANG</last-name><first-name>Ji Eun</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="07" designation="us-only"><addressbook><last-name>JU</last-name><first-name>Mi Kyeong</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="08" designation="us-only"><addressbook><last-name>KIM</last-name><first-name>Won Tae</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="09" designation="us-only"><addressbook><last-name>LEE</last-name><first-name>Youn Woo</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="10" designation="us-only"><addressbook><last-name>KIM</last-name><first-name>Junhwan</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>YUHAN CORPORATION</orgname><role>03</role><address><city>Seoul</city><country>KR</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/KR2020/016842</doc-number><date>20201125</date></document-id><us-371c12-date><date>20220525</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">A fusion protein including a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition containing the same are disclosed. The GDF15 variant or long-acting GDF15 fusion protein is superior to conventional GDF15 variants in terms of in vitro efficacy, binding affinity for GDF15 receptors, and body weight loss effect. Therefore, a pharmaceutical composition containing, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or a dimer of the fusion protein, causes appetite suppression, and thus can be effectively used as a therapeutic agent for metabolic diseases or obesity. Furthermore, the pharmaceutical composition can be used in combination therapy or the like with chemical drugs and other therapeutic agents for metabolic diseases, and can be effectively used in combination therapy with conventional therapeutic agents for metabolic diseases or obesity.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="75.95mm" wi="158.75mm" file="US20230002460A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="179.75mm" wi="152.15mm" file="US20230002460A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="182.37mm" wi="150.54mm" file="US20230002460A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="181.36mm" wi="138.94mm" file="US20230002460A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="200.24mm" wi="141.65mm" file="US20230002460A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="184.57mm" wi="154.26mm" file="US20230002460A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="214.12mm" wi="112.18mm" orientation="landscape" file="US20230002460A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="227.75mm" wi="119.97mm" orientation="landscape" file="US20230002460A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="220.81mm" wi="118.45mm" orientation="landscape" file="US20230002460A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CROSS REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application is a national stage application of PCT/KR2020/016842 filed Nov. 25, 2020, which claims priority based on Korean Patent Application No. 10-2019-0153680 filed Nov. 25, 2019.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">SEQUENCE LISTING</heading><p id="p-0003" num="0002">The content of the electronically submitted sequence listing, file name: Sequence_Listing_As_Filed.txt; size: 218,630 bytes; and date of creation: Apr. 15, 2022, filed herewith, is incorporated herein by reference in its entirety.</p><heading id="h-0003" level="1">TECHNICAL FIELD</heading><p id="p-0004" num="0003">The present invention relates to a fusion protein that includes a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition comprising the same.</p><heading id="h-0004" level="1">BACKGROUND ART</heading><p id="p-0005" num="0004">Growth differentiation factor-15 (GDF15) is also called macrophage inhibitory cytokine-1 (MIC-1), placental bone morphogenetic protein (PBMP), or nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1), and is a protein that is a member of the transforming growth factor-beta (TGF-&#x3b2;) superfamily.</p><p id="p-0006" num="0005">Recently, study results have shown that GDF15 inhibits dietary intake through binding to GDNF family receptor alpha-like (GFRAL) and ret proto-oncogene (RET), which are specifically expressed in brain tissue, and thus results in body weight loss (Tsai V W, et al., PLoS One 2013; 8(2): e55174; U.S. Pat. No. 8,192,735). In addition, several studies have demonstrated that GDF15 has an excellent body weight loss effect in a case of being administered to various obese animal models, and have identified that in addition to such an effect, GDF15 further has metabolic advantages such as lowering blood glucose level, improving lipid level, and improving insulin resistance.</p><p id="p-0007" num="0006">However, the wild-type GDF15 is problematic in that in a case where it is used medically, high frequency of administration is needed due to its short in vivo half-life. Accordingly, efforts are being made to develop long-acting formulations that are intended to increase an in vivo half-life of GDF15.</p><p id="p-0008" num="0007">Meanwhile, among several techniques of producing long-acting formulations, an immunoglobulin Fc fusion technique is most widely used in that it results in increased in vivo half-life and there is little concern about adverse effects such as toxicity or induction of immune responses. To develop an immunoglobulin Fc-fused GDF15 protein into a long-acting therapeutic drug, the following several conditions must be satisfied.</p><p id="p-0009" num="0008">First, decrease in in vitro activity caused by fusion should be minimized. It is known that activity of GDF15 fusion proteins varies greatly depending on fusion site. Therefore, activity of Fc-fused GDF15 proteins, in which a mutation has been introduced into the GDF15, may vary depending on whether fusion has occurred or fusion site. Second, fusion should result in increased in vivo half-life, and the increased in vivo half-life should display a pharmacokinetic profile which enables administration at an interval of once a week in humans. Third, considering that most biopharmaceuticals may cause immunogenicity in patients, risk of immunogenicity caused by a fusion linker or mutation should be minimized. Fourth, there should be no stability problems due to fusion site or mutation introduction. Fifth, since an unwanted immune response may occur depending on isotypes of fused immunoglobulin, an alternative thereto is required.</p><p id="p-0010" num="0009">While making efforts to improve physiological activity and stability of GDF15, the present inventors have identified that in a case where a mutation is introduced at a particular location of GDF15 and an immunoglobulin Fc region is bound thereto, the GDF15 has enhanced activity and increased in vivo half-life, and thus have completed the present invention.</p><heading id="h-0005" level="1">DISCLOSURE OF INVENTION</heading><heading id="h-0006" level="1">Technical Problem</heading><p id="p-0011" num="0010">An object of the present invention is to provide a GDF15 variant having improved physiological activity and stability, and a long-acting GDF15 fusion protein.</p><p id="p-0012" num="0011">Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome, comprising, as an active ingredient, the GDF15 variant or the long-acting GDF15 fusion protein.</p><heading id="h-0007" level="1">Solution to Problem</heading><p id="p-0013" num="0012">To achieve the above objects, in an aspect of the present invention, there is provided a GDF15 variant represented by Formula (I).</p><p id="p-0014" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>N-terminal extension domain-core domain&#x2003;&#x2003;(I)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0015" num="0013">In another aspect of the present invention, there is provided a long-acting GDF15 fusion protein, in which the GDF15 variant is bound to human IgG Fc or a variant thereof.</p><p id="p-0016" num="0014">In yet another aspect of the present invention, there is provided a fusion protein dimer, comprising two of the long-acting GDF15 fusion protein.</p><p id="p-0017" num="0015">In still yet another aspect of the present invention, there is provided an isolated nucleic acid molecule, encoding the GDF15 variant or the GDF15 fusion protein.</p><p id="p-0018" num="0016">In still yet another aspect of the present invention, there is provided an expression vector, comprising the nucleic acid molecule.</p><p id="p-0019" num="0017">In still yet another aspect of the present invention, there is provided a host cell, comprising the expression vector.</p><p id="p-0020" num="0018">In still yet another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome, comprising, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer.</p><heading id="h-0008" level="1">Advantageous Effects of Invention</heading><p id="p-0021" num="0019">The GDF15 variant or the long-acting GDF15 fusion protein, according to the present invention, is superior to conventional GDF15 variants in terms of in vitro efficacy, binding affinity for GDF15 receptors, and body weight loss effect.</p><p id="p-0022" num="0020">Therefore, a pharmaceutical composition, which comprises, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer, of the present invention, causes appetite suppression, and thus can be effectively used as a therapeutic agent for metabolic diseases or obesity.</p><p id="p-0023" num="0021">Furthermore, the pharmaceutical composition, which comprises, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer, can be used in combination therapy or the like with chemical drugs and other therapeutic agents for metabolic diseases, and can be effectively used in combination therapy with conventional therapeutic agents for metabolic diseases or obesity.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0009" level="1">BRIEF DESCRIPTION OF DRAWINGS</heading><p id="p-0024" num="0022"><figref idref="DRAWINGS">FIG. <b>1</b></figref> illustrates results obtained by comparing, in terms of activity, long-acting GDF15 fusion proteins (dimers: FM4, FM4-1, FM4-2, and FM4-3) in which asparagine (N), which is the amino acid at position 56 in mature GDF15, and/or aspartic acid (D), which is the amino acid at position 103 in mature GDF15, is substituted with another amino acid.</p><p id="p-0025" num="0023"><figref idref="DRAWINGS">FIG. <b>2</b></figref> illustrates results obtained by comparing, in terms of activity, long-acting GDF15 fusion proteins (dimers: FM9, FM13, FM14, FM15, and FM16) in which serine (S), which is the amino acid at position 64 in mature GDF15 is substituted with another amino acid.</p><p id="p-0026" num="0024"><figref idref="DRAWINGS">FIG. <b>3</b></figref> illustrates results obtained by comparing, in terms of activity, long-acting GDF15 fusion proteins (dimers: FM4, FM5, and FM9).</p><p id="p-0027" num="0025"><figref idref="DRAWINGS">FIG. <b>4</b></figref> illustrates results obtained by comparing, in terms of binding affinity for GDF15 receptors (GFRAL and RET), long-acting GDF15 fusion proteins (dimers: FM4, FM5, and FM9).</p><p id="p-0028" num="0026"><figref idref="DRAWINGS">FIG. <b>5</b></figref> illustrates results obtained by comparing, in terms of activity, long-acting GDF15 fusion proteins (dimers: FM1, and FM10).</p><p id="p-0029" num="0027"><figref idref="DRAWINGS">FIG. <b>6</b></figref> illustrates results obtained by comparing, in terms of activity, long-acting GDF15 fusion proteins (dimers: FM2, and FM11).</p><p id="p-0030" num="0028"><figref idref="DRAWINGS">FIG. <b>7</b></figref> illustrates results obtained by comparing, in terms of activity, long-acting GDF15 fusion proteins (dimers: FM3, and FM12).</p><p id="p-0031" num="0029"><figref idref="DRAWINGS">FIG. <b>8</b></figref> illustrates results obtained by comparing, in terms of binding affinity for GDF15 receptors (GFRAL and RET), long-acting GDF15 fusion proteins (dimers: FM10 and FM11).</p><p id="p-0032" num="0030"><figref idref="DRAWINGS">FIG. <b>9</b></figref> illustrates results obtained by comparing, in terms of activity depending on linker type and length, long-acting GDF15 fusion proteins (dimers: FM9-1, FM9-2, FM9-3, FM9-4, FM9-5, and FM9-6).</p><p id="p-0033" num="0031"><figref idref="DRAWINGS">FIG. <b>10</b></figref> illustrates results obtained by comparing, in terms of activity depending on linker type and length, long-acting GDF15 fusion proteins (dimers: FM11-1, FM11-2, FM11-3, FM11-4, FM11-5, and FM11-6).</p><p id="p-0034" num="0032"><figref idref="DRAWINGS">FIG. <b>11</b></figref> illustrates results obtained by comparing long-acting GDF15 fusion proteins (dimers; FM9-4, FM9-6, FM11-4, and FM11-6) in terms of change of body weight (%) in diet-induced obese mice (DIO mice), by repeated administration.</p><p id="p-0035" num="0033"><figref idref="DRAWINGS">FIG. <b>12</b></figref> illustrates results obtained by comparing long-acting GDF15 fusion proteins (dimers; FM9-6) in terms of change of body weight (%) in diet-induced obese mice (DIO mice), by single administration.</p><p id="p-0036" num="0034"><figref idref="DRAWINGS">FIG. <b>13</b></figref> illustrates results obtained by comparing long-acting GDF15 fusion proteins (dimers; FM9-6) in terms of change of body weight (%) in ob/ob mice, by repeated administration.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0010" level="1">BEST MODE FOR CARRYING OUT THE INVENTION</heading><p id="p-0037" num="0035">Hereinafter, the present invention will be described in more detail.</p><p id="p-0038" num="0036">GDF15 Variant</p><p id="p-0039" num="0037">In an aspect of the present invention, there is provided a GDF15 variant represented by Formula (I):</p><p id="p-0040" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>N-terminal extension domain-core domain&#x2003;&#x2003;(I).<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0041" num="0038">In Formula (I),</p><p id="p-0042" num="0039">the N-terminal extension domain is a polypeptide consisting of any one amino acid sequence of SEQ ID NOs: 3 to 5; and</p><p id="p-0043" num="0040">the core domain is a polypeptide represented by SEQ ID NO: 20, or a polypeptide derived from SEQ ID NO: 20 in which any one amino acid selected from the group consisting of amino acids at positions 15, 50, 58, 97, and combinations thereof in the amino acid sequence of SEQ ID NO: 20 is substituted with another amino acid;</p><p id="p-0044" num="0041">wherein arginine (R), which is the amino acid at position 15, may be substituted with alanine (A), aspartic acid (D), asparagine (N), cysteine (C), glutamic acid (E), glutamine (Q), glycine (G), histidine (H), isoleucine (I), leucine (L), lysine (K), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y), or valine (V),</p><p id="p-0045" num="0042">asparagine (N), which is the amino acid at position 50, may be substituted with alanine, arginine (R), aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine,</p><p id="p-0046" num="0043">serine (S), which is the amino acid at position 58, may be substituted with alanine, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, or valine, and</p><p id="p-0047" num="0044">aspartic acid (D), which is the amino acid at position 97, may be substituted with alanine, arginine, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.</p><p id="p-0048" num="0045">As used herein, the term &#x201c;core domain&#x201d; refers to a polypeptide having an amino acid sequence from positions 7 to 112 in the amino acid sequence of GDF15 of SEQ ID NO: 1, including a polypeptide represented by SEQ ID NO: 20, or a polypeptide derived from SEQ ID NO: 20 in which any one amino acid selected from the group consisting of amino acids at positions 15, 50, 58, 97, and combinations thereof in the amino acid sequence of SEQ ID NO: 20 is substituted with another amino acid. The first core domain may consist of the amino acid sequence of SEQ ID NO: 2.</p><p id="p-0049" num="0046">Specifically, the core domain may include any one variation selected from the group consisting of the following variations (1) to (6):</p><p id="p-0050" num="0047">(1) a variation in which arginine (R), which is the amino acid at position 15 in the amino acid sequence of SEQ ID NO: 20, is substituted with asparagine (N);</p><p id="p-0051" num="0048">(2) a variation in which asparagine (N), which is the amino acid at position 50 in the amino acid sequence of SEQ ID NO: 20, is substituted with leucine (L);</p><p id="p-0052" num="0049">(3) a variation in which serine (S), which is the amino acid at position 58 in the amino acid sequence of SEQ ID NO: 20, is substituted with lysine (K), arginine (R), asparagine (N), aspartic acid (D), glutamic acid (E), cysteine (C), or leucine (L);</p><p id="p-0053" num="0050">(4) a variation in which aspartic acid (D), which is the amino acid at position 97 in the amino acid sequence of SEQ ID NO: 20, is substituted with leucine (L);</p><p id="p-0054" num="0051">(5) a variation in which asparagine (N), which is the amino acid at position 50 in the amino acid sequence of SEQ ID NO: 20, and aspartic acid (D), which is the amino acid at position 97 in the amino acid sequence of SEQ ID NO: 20, are each substituted with cysteine (C) or serine (S); and</p><p id="p-0055" num="0052">(6) a variation in which arginine (R), which is the amino acid at position 15 in the amino acid sequence of SEQ ID NO: 20, is substituted with asparagine (N), and serine (S), which is the amino acid at position 58 in the amino acid sequence of SEQ ID NO: 20, is substituted with lysine (K) or arginine (R).</p><p id="p-0056" num="0053">Here, the core domain may consist of any one amino acid sequence selected from SEQ ID NOs: 6 to 19.</p><p id="p-0057" num="0054">The N-terminal extension domain is a domain bound to the N-terminus of the above-described core domain, and may be a polypeptide consisting of any one amino acid sequence of SEQ ID NOs: 3 to 5.</p><p id="p-0058" num="0055">As used herein, the expression &#x201c;&#x394;N2&#x201d; may also be indicated as &#x201c;delta N2&#x201d;, meaning that in the amino acid sequence of human GDF15 represented by SEQ ID NO: 1, the amino acids at positions 1 and 2 are deleted. In a case where &#x394;N2 is expressed as an N-terminal extension domain, it may be expressed as &#x201c;NGDH&#x201d; (SEQ ID NO: 112).</p><p id="p-0059" num="0056">As used herein, the expression &#x201c;&#x394;N3, WS insertion, G4N, D5S, H6T&#x201d; may also be indicated as &#x201c;delta N3, WS insertion, G4N, D5S, H6T&#x201d;, meaning that in the amino acid sequence of human GDF15 represented by SEQ ID NO: 1, the amino acids at positions 1 to 3 are deleted, and tryptophan and serine are inserted therein; glycine, which is the amino acid at position 4, is substituted with asparagine; aspartic acid, which is the amino acid at position 5, is substituted with serine; and histidine, which is the amino acid at position 6, is substituted with threonine. In a case where the &#x394;N3, WS insertion, G4N, D5S, H6T is expressed as an N-terminal extension domain, it may be indicated as &#x201c;WSNST&#x201d; (SEQ ID NO: 113).</p><p id="p-0060" num="0057">As used herein, the expression &#x201c;&#x394;N3, G4N, D5S, H6T&#x201d; may also be indicated as &#x201c;delta N3, G4N, D5S, H6T&#x201d;, meaning that in the amino acid sequence of human GDF15 represented by SEQ ID NO: 1, the amino acids at positions 1 to 3 are deleted; glycine, which is the amino acid at position 4, is substituted with asparagine; aspartic acid, which is the amino acid at position 5, is substituted with serine; and histidine, which is the amino acid at position 6, is substituted with threonine. In a case where the &#x201c;&#x394;N3, G4N, D5S, H6T&#x201d; is expressed as an N-terminal extension domain, it may be expressed as &#x201c;NST.&#x201d;</p><p id="p-0061" num="0058">The GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a core domain consisting of any one amino acid sequence selected from SEQ ID NOs: 6 to 20. In addition, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 4 and a core domain consisting of any one amino acid sequence selected from SEQ ID NOs: 6 to 20. Furthermore, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 5 and a core domain consisting of any one amino acid sequence selected from SEQ ID NO: 6 to 19.</p><p id="p-0062" num="0059">Preferably, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a core domain consisting of an amino acid sequence represented by SEQ ID NO: 8, 9, or 20. In addition, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 4 and a core domain consisting of an amino acid sequence represented by SEQ ID NO: 8, 9, or 20. Furthermore, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 5 and a core domain consisting of any one amino acid sequence selected from SEQ ID NOs: 6, 7, and 10 to 19. Here, the GDF15 variant may consist of any one amino acid sequence selected from SEQ ID NOs: 21 to 39.</p><p id="p-0063" num="0060">Long-Acting GDF15 Fusion Protein</p><p id="p-0064" num="0061">In another aspect of the present invention, there is provided a long-acting GDF15 fusion protein, in which the GDF15 variant is bound to human IgG Fc or a variant thereof.</p><p id="p-0065" num="0062">The human IgG Fc or a variant thereof may be Fc of IgG1, IgG2, IgG3, or IgG4, or a variant thereof. Specifically, the human IgG Fc or a variant thereof may be human IgG1 Fc or a variant thereof, and the human IgG1 Fc may consist of an amino acid sequence represented by SEQ ID NO: 41.</p><p id="p-0066" num="0063">The human IgG Fc or a variant thereof may be a contiguous amino acid sequence that is 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41, or a fragment of the Fc including a CH3 domain. In certain embodiments, the human IgG Fc or a variant thereof may be a contiguous amino acid sequence that is 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41, or a fragment of the Fc including a CH2 domain and a CH3 domain. In certain embodiments, the human IgG Fc or a variant thereof may be a contiguous amino acid sequence that is 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41, or a fragment of the Fc including a partial hinge region, a CH2 domain, and a CH3 domain. In certain embodiments, the human IgG Fc or a variant thereof may have an amino acid sequence that is 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41.</p><p id="p-0067" num="0064">The IgG Fc or a variant thereof includes a first polypeptide including an IgG1 Fc sequence, the IgG Fc sequence including a CH3 sequence that includes at least one engineered protuberance; and a second polypeptide including an IgG1 Fc sequence, the IgG Fc sequence including a CH3 sequence that includes at least one engineered cavity, in which the first polypeptide dimerizes with the second polypeptide via positioning of the protuberance of the first polypeptide into the cavity of the second polypeptide.</p><p id="p-0068" num="0065">Specifically, the first polypeptide may include an engineered protuberance that allows binding to another IgG Fc polypeptide (for example, second polypeptide) including an engineered cavity. The second polypeptide may include an engineered cavity that allows binding to another IgG Fc polypeptide (for example, first polypeptide) including an engineered protuberance. In addition, the protuberance of the first polypeptide and the cavity of the second polypeptide may be each engineered into a CH3 domain of IgG Fc. Here, the protuberance of the first polypeptide and the cavity of the second polypeptide are neither connected nor bound to the GDF15 variant.</p><p id="p-0069" num="0066">The engineered protuberance may include at least one substitution in the amino acid sequence of human IgG1 Fc having an amino acid sequence represented by SEQ ID NO: 41. Here, the amino acid positions are numbered according to EU numbering. The substitution may be present at a position selected from the group consisting of amino acid residues 347, 366, and 394. For example, the substitution may be any one selected from the group consisting of Q347W/Y, T366W/Y, T394W/Y, and combinations thereof. In addition, the engineered cavity may include at least one substitution in corresponding amino acids in the human IgG1 Fc sequence, and the substitution may be present at a position selected from the group consisting of amino acid residues 366, 368, 394, 405, and 407. For example, the substitution may be any one selected from the group consisting of T366S, L368A, T394S, F405T/V/A, Y407T/V/A, and combinations thereof.</p><p id="p-0070" num="0067">Preferably, the protuberance may include the substitution T366W/Y, and the cavity may include any one substitution selected from the group consisting of T366S, L368A, Y407T/V/A, and combinations thereof. For example, the protuberance may include the substitution T366W/Y, and the cavity may include the substitution Y407T/V/A. In addition, the protuberance may include the substitution T366Y, and the cavity may include the substitution Y407T. In addition, the protuberance may include the substitution T366W, and the cavity may include the substitution Y407A. In addition, the protuberance may include the substitution T394Y, and the cavity may include the substitution Y407T.</p><p id="p-0071" num="0068">The first polypeptide may consist of any one amino acid sequence selected from SEQ ID NOs: 42, 44, and 46, and the second polypeptide may consist of any one amino acid sequence selected from SEQ ID NOs: 43, 45, and 47.</p><p id="p-0072" num="0069">The protuberance is referred to as &#x201c;knob&#x201d; and the cavity is referred to as &#x201c;hole&#x201d;.</p><p id="p-0073" num="0070">The first polypeptide is Fc &#x2018;knob&#x2019; including an engineered protuberance, and the second polypeptide is Fc &#x2018;hole&#x2019; including an engineered protuberance. The first and second polypeptides may be physically associated with each other via non-covalent interactions (for example, hydrophobic effects, such as hydrophobic interaction between the knob and hole regions of the Fc), covalent bonds (for example, disulfide bonds such as one or two or more disulfide bonds between hinge regions of the Fc in the first and second polypeptides), or both.</p><p id="p-0074" num="0071">As used herein, the term &#x201c;dimer&#x201d; refers to a protein complex including at least two polypeptides. Each of these polypeptides includes an N-terminus and a C-terminus. At least two polypeptides may be associated with each other via one or both of covalent and non-covalent (for example, electrostatic, &#x3c0;-effects, van der Waals forces, and hydrophobic effects) interactions. The two polypeptides may have the same amino acid sequence or may be different from each other. In a case where the two polypeptides are identical to each other, the dimer is referred to as a (homo)dimer; and in a case where the two polypeptides are different from each other, the dimer is referred to as a heterodimer.</p><p id="p-0075" num="0072">The human IgG Fc or a variant thereof may be a heterodimer including a first polypeptide and a second polypeptide; and the heterodimer may be a heterodimer formed of A-1 (SEQ ID NO: 42) and A-2 (SEQ ID NO: 43), a heterodimer formed of B-1 (SEQ ID NO: 44) and B-2 (SEQ ID NO: 45), or a heterodimer formed of C-1 (SEQ ID NO: 46) and C-2 (SEQ ID NO: 47).</p><p id="p-0076" num="0073">In addition, the IgG Fc or a variant thereof may include an additional mutation, to improve properties of a long-acting GDF15 fusion protein. Specifically, a heterodimer consisting of the first polypeptide and the second polypeptide may include an additional mutation.</p><p id="p-0077" num="0074">For example, the IgG Fc or a variant thereof may include mutation(s) that abolish (for example, decrease or eliminate) IgG effector function. Specifically, an Fc partner sequence may include mutation(s) that abolish effector functions such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). For example, the mutations E233A and L235A may be introduced into the IgG Fc formed of A-1 and A-2 or a variant thereof (which is a heterodimer), to eliminate IgG1 effector function. The heterodimer formed of B-1 and B-2, which includes the mutation N297A, can be used to eliminate N-linked glycans. Into the heterodimer formed of C-1 and C-2 may be introduced the mutations L234A, L235A, and N297A, to eliminate IgG1 effector function and N-linked glycans.</p><p id="p-0078" num="0075">Binding between the GDF15 variant and the IgG Fc or a variant thereof may be such that the C-terminus of the first polypeptide or the C-terminus of the second polypeptide, in the IgG Fc or a variant thereof, is bound to the N-terminus of the GDF15 variant. In addition, binding between the GDF15 variant and the IgG Fc or a variant thereof may be such that the N-terminus of the first polypeptide or the N-terminus of the second polypeptide, in the IgG Fc or a variant thereof, is bound to the C-terminus of the GDF15 variant. Preferably, binding between the GDF15 variant and the IgG Fc or a variant thereof may be such that the C-terminus of the first polypeptide in the IgG Fc or a variant thereof is bound to the N-terminus of the GDF15 variant.</p><p id="p-0079" num="0076">In addition, binding between the GDF15 variant and the IgG Fc or a variant thereof may be made through a linker. The linker may be a peptide that consists of 10 to 50 amino acid residues, including glycine, serine, alanine, and glutamic acid residues. The linker may include (G4S)<sub>n</sub>, where n may be an integer of 1 to 10 or an integer of 2 to 7. For example, n may be 2, 3, 4, 5, 6, or 7. In an embodiment of the present invention, a linker including (G4S)<sub>5</sub>, which is a case where n is an integer of 5, was used.</p><p id="p-0080" num="0077">As an example of a suitable linker other than the linker including (G4S)<sub>n </sub>(SEQ ID NO: 48), a linker including GS(G4S)<sub>n </sub>(SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94), GS(EEEA)<sub>n </sub>(SEQ ID NO: 95), (EEEA)<sub>n </sub>(SEQ ID NO: 110), GS(EAAAK)<sub>n </sub>(SEQ ID NO: 97), (EAAAK)<sub>n </sub>(SEQ ID NO: 111), or GSGGSS(PT)<sub>n </sub>(SEQ ID NO: 96) may be mentioned, where n may be an integer of 1 to 10. However, the suitable linker is not limited thereto. In an embodiment of the present invention, a linker including GS(EEEA)<sub>6</sub>, which is a case where n is an integer of 6, or a linker including GS(EAAAK)<sub>5</sub>, which is a case where n is an integer of 5, was used.</p><p id="p-0081" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="196pt" align="left"/><tbody valign="top"><row><entry/><entry>Specifically,&#x2003;the&#x2003;linker&#x2003;may&#x2003;be</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;48)</entry></row><row><entry/><entry>GGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;92)</entry></row><row><entry/><entry>GSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;93)</entry></row><row><entry/><entry>GSGGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;94)</entry></row><row><entry/><entry>GSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;95)</entry></row><row><entry/><entry>GSEEEAEEEAEEEAEEEAEEEAEEEA,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;96)</entry></row><row><entry/><entry>GSGGSSPTPTPTPTPTPTPTPTPTPT,</entry></row><row><entry/><entry>or</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;97)</entry></row><row><entry/><entry>GSEAAAKEAAAKEAAAKEAAAKEAAAK.</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>Preferably,&#x2003;the&#x2003;linker&#x2003;may&#x2003;be</entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;48)</entry></row><row><entry/><entry>GGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;95)</entry></row><row><entry/><entry>GSEEEAEEEAEEEAEEEAEEEAEEEA,</entry></row><row><entry/><entry>or</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;97)</entry></row><row><entry/><entry>GSEAAAKEAAAKEAAAKEAAAKEAAAK.</entry></row></tbody></tgroup></table></tables></p><p id="p-0082" num="0078">The long-acting GDF15 fusion protein includes one GDF15 variant per heterodimer consisting of a first polypeptide and a second polypeptide. The GDF15 variant may include at least one N-linked glycan.</p><p id="p-0083" num="0079">The long-acting GDF15 fusion protein may include i) a GDF15 variant consisting of any one amino acid sequence selected from SEQ ID NOs: 21 to 39, ii) a first polypeptide consisting of any one amino acid sequence selected from SEQ ID NOs: 42, 44, and 46, and iii) a second polypeptide consisting of any one amino acid sequence selected from SEQ ID NOs: 43, 45, and 47.</p><p id="p-0084" num="0080">Preferably, the long-acting GDF15 fusion protein may include i) a GDF15 variant consisting of any one amino acid sequence selected from SEQ ID NOs: 21 to 39, ii) a linker consisting of the amino acid sequence of SEQ ID NO: 48, iii) a first polypeptide consisting of the amino acid sequence of SEQ ID NO: 42, and iv) a second polypeptide consisting of the amino acid sequence of SEQ ID NO: 43.</p><p id="p-0085" num="0081">Still preferably, the long-acting GDF15 fusion protein may include i) a GDF15 variant consisting of any one amino acid sequence selected from SEQ ID NOs: 21 to 39, ii) a linker consisting of any one amino acid sequence selected from SEQ ID NOs: 92 to 97, iii) a first polypeptide consisting of the amino acid sequence of SEQ ID NO: 46, and iv) a second polypeptide consisting of the amino acid sequence of SEQ ID NO: 47.</p><p id="p-0086" num="0082">Fusion Protein Dimer</p><p id="p-0087" num="0083">In still yet another aspect of the present invention, there is provided a fusion protein dimer, comprising two of the long-acting GDF15 fusion protein. Specifically, the two long-acting GDF15 fusion proteins are dimerized through GDF15-GDF15 interaction, and this was designated &#x201c;fusion protein dimer&#x201d;.</p><p id="p-0088" num="0084">Nucleic Acid Molecule, Expression Vector, and Host Cell</p><p id="p-0089" num="0085">In still yet another aspect of the present invention, there is provided an isolated nucleic acid molecule, encoding the GDF15 variant or the long-acting GDF15 fusion protein.</p><p id="p-0090" num="0086">As used herein, the term &#x201c;isolated nucleic acid molecule&#x201d; refers to a nucleic acid molecule of the present invention that has been separated from at least about 50% of proteins, lipids, carbohydrates, or other materials with which it is naturally found when the entire nucleic acid is isolated from source cells; is operably linked to a polynucleotide which it is not linked to in nature; or does not occur in nature as part of a larger polynucleotide sequence. Specifically, the isolated nucleic acid molecule of the present invention is substantially free from any other contaminating nucleic acid molecules, or other contaminants that are found in its natural environment and would interfere with its use in polypeptide production, or its therapeutic, diagnostic, prophylactic, or research application.</p><p id="p-0091" num="0087">Here, the isolated nucleic acid molecule that encodes the GDF15 variant or the long-acting GDF15 fusion protein may have different sequences due to codon redundancy. In addition, the isolated nucleic acid molecule may be appropriately modified or may have a nucleotide added to the N-terminus or C-terminus, depending on purposes, as long as it can produce the GDF15 variant or the long-acting GDF15 fusion protein.</p><p id="p-0092" num="0088">In still yet another aspect of the present invention, there is provided an expression vector, comprising the isolated nucleic acid molecule that encodes the GDF15 variant or the long-acting GDF15 fusion protein.</p><p id="p-0093" num="0089">As used herein, the term &#x201c;expression vector&#x201d; refers to a vector which is suitable for transformation of a host cell and contains a nucleic acid sequence that directs or controls expression of an inserted heterologous nucleic acid sequence. The vector includes linear nucleic acids, plasmids, phagemids, cosmids, RNA vectors, viral vectors, and analogs thereof. Examples of the viral vector include, but are not limited to, a retrovirus, an adenovirus, and an adeno-associated virus.</p><p id="p-0094" num="0090">As used herein, the term &#x201c;expression of a heterologous nucleic acid sequence&#x201d; or &#x201c;expression&#x201d; of a target protein refers to transcription of an inserted DNA sequence, translation of an mRNA transcript, and production of a fusion protein product, an antibody, or an antibody fragment.</p><p id="p-0095" num="0091">A useful expression vector may be RcCMV (Invitrogen, Carlsbad) or a variant thereof. The useful expression vector may include a human cytomegalovirus (CMV) promoter for promoting continuous transcription of a target gene in mammalian cells, and a bovine growth hormone polyadenylation signal sequence for increasing a post-transcriptional RNA stability level.</p><p id="p-0096" num="0092">In still yet another aspect of the present invention, there is provided a host cell, comprising the expression vector.</p><p id="p-0097" num="0093">As used herein, the term &#x201c;host cell&#x201d; refers to a prokaryotic or eukaryotic cell into which a recombinant expression vector can be introduced. As used herein, the term &#x201c;transformed&#x201d; or &#x201c;transfected&#x201d; means that a nucleic acid (for example, vector) is introduced into a cell by a number of techniques known in the art.</p><p id="p-0098" num="0094">The host cell may be transformed or transfected with a DNA sequence of the present invention, and may be used for expression and/or secretion of a target protein. Examples of the host cell that can be used in the present invention may include immortal hybridoma cells, NS/0 myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, CAP cells (human amniotic fluid-derived cells), and COS cells.</p><p id="p-0099" num="0095">Pharmaceutical Composition</p><p id="p-0100" num="0096">In a still yet another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome, comprising, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer.</p><p id="p-0101" num="0097">The pharmaceutical composition of the present invention can be administered via any route. The composition of the present invention may be provided to an animal either directly (for example, topically, by injection, implantation, or local administration to a tissue site) or systemically (for example, by parenteral or oral administration) using any appropriate means. In a case where the composition of the present invention is parenterally provided, such as by intravenous, subcutaneous, ophthalmic, intraperitoneal, intramuscular, rectal, intraorbital, intracerebral, intracranial, intraspinal, intraventricular, intrathecal, intracisternal, intracapsular, intranasal, or aerosol administration, the composition may be aqueous or include a portion of a physiologically applicable body fluid suspension or solution. Accordingly, since a carrier or vehicle is physiologically acceptable, it may be added to the composition and delivered to a patient. Therefore, physiological saline may be generally included as a body fluid-like carrier for formulations.</p><p id="p-0102" num="0098">In addition, frequency of administration may vary depending on pharmacokinetic parameters of the GDF15 variant in a formulation used. Typically, physicians would administer the pharmaceutical composition until the dose thereof reaches a dose that achieves a desired effect. Thus, the pharmaceutical composition may be administered as a single dose, or two or more doses at time intervals (which may or may not contain an equal amount of a target fusion protein), or may be administered as continuous infusion through an implantable device or catheter. Further refinement of an appropriate dose is routinely made by those skilled in the art and falls within the scope of work which is routinely performed by them.</p><p id="p-0103" num="0099">In addition, a unit dose of the fusion protein in humans is 0.01 &#x3bc;g to 100 mg/kg body weight, and specifically, 1 &#x3bc;g to 10 mg/kg body weight. Although the above-mentioned amount is an optimal amount, the amount may vary depending on a disease to be treated, or presence or absence of adverse effects. An optimal dose may be determined using a conventional experiment. Administration of the fusion protein may be made by periodic bolus injections, or continuous intravenous, subcutaneous, or intraperitoneal administration from an external reservoir (for example, intravenous bag) or an internal reservoir (for example, biodegradable implant).</p><p id="p-0104" num="0100">In addition, the fusion protein of the present invention may be administered to a subject recipient together with other biologically active molecules. However, an optimal combination of the fusion protein and other molecules, and dosage forms and precise doses thereof may be determined by conventional experiments well known in the art.</p><p id="p-0105" num="0101">In still yet another aspect of the present invention, there is provided a use of the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer, for prevention or treatment of diabetes, obesity, dyslipidemia, or metabolic syndrome.</p><p id="p-0106" num="0102">In still yet another aspect of the present invention, there is provided a use of the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer, for manufacture of a medicament for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome.</p><p id="p-0107" num="0103">In still yet another aspect of the present invention, there is provided a method for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome, comprising a step of administering, to an individual, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer.</p><p id="p-0108" num="0104">Dose, frequency of administration, and route of administration of the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer are the same as described above. The individual may be an individual suffering from diabetes, obesity, dyslipidemia, or metabolic syndrome. In addition, the individual may be a mammal, preferably a human.</p><heading id="h-0011" level="1">MODE FOR THE INVENTION</heading><p id="p-0109" num="0105">Hereinafter, for better understanding of the present invention, the present invention will be described in detail by way of examples. However, the examples according to the present invention may be modified in a variety of different forms, and the scope of the present invention should not be construed as being limited to the following examples.</p><heading id="h-0012" level="1">Example 1: Production of Long-Acting GDF15 Fusion Protein</heading><heading id="h-0013" level="1">Example 1.1: Gene Cloning</heading><p id="p-0110" num="0106">In general, in a case where a substance is fused to long-acting Fc or albumin to increase its half-life, the fusion results in a decrease in activity of the substance. To improve this, various GDF15 variants were designed.</p><p id="p-0111" num="0107">First, first polypeptides were prepared by performing substitutions of respective amino acids at positions 32, 51, 56, 60, 64, 90, 92, 93, 97, 101, and 103 in GDF15, which are predicted to have a large effect on protein activity through three-dimensional structure analysis of GDF15, and causing the resulting GDF15's to be bound to IgG1 Fc_knob, and these first polypeptides are shown in Table 1 below.</p><p id="p-0112" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 1</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Changes in </entry><entry/><entry/><entry/></row><row><entry>sequence </entry><entry/><entry/><entry>SEQ ID NO of</entry></row><row><entry>of GDF15</entry><entry>Fusion carrier</entry><entry>Linker sequence</entry><entry>fusion protein</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>&#x394;N2</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 49</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, N56C, </entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 65</entry></row><row><entry>D103C</entry><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, W32F</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 69</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, W32H</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 70</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, W32Y</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 71</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Q51H</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 72</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Q51L</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 73</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Q51E</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 74</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Q51N</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 75</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Q90H</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 76</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Q90E</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 77</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Q90K</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 78</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, D93E</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 79</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, D93L</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 80</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, D93N</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 81</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, D93Q</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 82</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Q60L</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 83</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Q60N</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 84</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, S64K</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 54</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, S64Q</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 85</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, T92S</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 86</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, T92E</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 87</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, S97N</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 88</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, S97Q</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 89</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Y101F</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 90</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry><entry/></row><row><entry>&#x394;N2, Y101Q</entry><entry>IgG1 Fc_knob </entry><entry>(G4S)<sub>5 </sub>(SEQ ID </entry><entry>SEQ ID NO: 91</entry></row><row><entry/><entry>(SEQ ID NO: 42)</entry><entry>NO: 48)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0113" num="0108">Specifically, to produce a first polypeptide (FM series) having a structure of Fc_knob-(G4S)<sub>5</sub>-GDF15 variant and a second polypeptide having Fc_hole structure, gene cloning was conducted using pcDNA3.3 (Invitrogen) expression vector that includes a gene encoding a first polypeptide consisting of any one amino acid sequence of SEQ ID NOs: 49, 60, 65, and 69 to 90 and a gene encoding a second polypeptide consisting of the amino acid sequence of SEQ ID NO: 43. Here, nucleotide sequences encoding the amino acid sequences of SEQ ID NOs: 43, 49, 60, 65, and 69 to 90 were synthesized by making a request to Macrogen, Inc.</p><heading id="h-0014" level="1">Example 1.2: Expression and Purification of Long-Acting GDF15 Fusion Protein (Dimer)</heading><p id="p-0114" num="0109">The pcDNA3.3 expression vector cloned in Example 1.1 was transiently transfected into ExpiCHO cell line (Invitrogen). Then, on Day 8, the cell culture was harvested and purified. To purify the first polypeptide and the second polypeptide in the harvest cell culture fluid (HCCF), affinity purification using Protein A resin was performed.</p><p id="p-0115" num="0110">Specifically, the HCCF was loaded onto MabSelect SuRe Protein A resin (GE Healthcare) equilibrated with 1&#xd7;PBS (pH 7.4), to induce binding. After completion of the binding between the first polypeptide and the second polypeptide, the MabSelect SuRe Protein A resin was washed with 1&#xd7;PBS (pH 7.4). Then, elution was performed using 0.1 M glycine (pH 3.0) solution, to obtain a final substance.</p><p id="p-0116" num="0111">The first polypeptide and the second polypeptide were neutralized to a level of about pH 8.0 using 1 M Tris-HCl solution. The first polypeptide and the second polypeptide were completely dimerized through knob-in-hole interaction, and this was designated &#x201c;long-acting GDF15 fusion protein&#x201d;. Two molecules of the long-acting GDF15 fusion protein were dimerized again through GDF15-GDF15 interaction, and this was designated &#x201c;fusion protein dimer&#x201d;.</p><heading id="h-0015" level="1">Example 2: Measurement of Activity of Long-Acting GDF15 Fusion Protein (Dimer)</heading><p id="p-0117" num="0112">Using a fusion protein that includes mature GDF15 consisting of the amino acid sequence of SEQ ID NO: 49, as a control, the long-acting GDF15 fusion proteins produced in Example 1 were compared in terms of GDF15 activity. The GDF15 activity was measured using a BRIGHT-GLO&#x2032; luciferase assay kit (Promega) and human embryonic kidney 293 (HEK293) cell line overexpressing GFRAL/RET/SRE-luc.</p><p id="p-0118" num="0113">Specifically, 1&#xd7;10<sup>5 </sup>HEK293 cells overexpressing GFRAL/RET/SRE-luc were dispensed into each well of a 96-well-plate in DMEM medium containing 10% FBS, and then incubated for 24 hours at 37&#xb0; C. and 5% CO<sub>2</sub>. After 24 hours, each medium in the 96-well-plate was replaced with 50 &#x3bc;l of serum-free medium, and incubated for 4 hours at 37&#xb0; C. and 5% CO<sub>2</sub>.</p><p id="p-0119" num="0114">In addition, each of the long-acting GDF15 fusion proteins produced in Example 1 was prepared by 3-fold serial dilution starting from a concentration of 2000 nM using serum-free medium. Then, 50 &#x3bc;l of the long-acting GDF15 fusion protein dilution was added to each well that contains 50 &#x3bc;l of the replaced serum-free medium and the GFRAL/RET/SRE-luc cell line, so that the actual concentration was obtained by 3-fold serial dilution starting from 1000 nM. Then, reaction was allowed to proceed for 4 hours at 37&#xb0; C. and 5% CO<sub>2</sub>. After 4 hours, each well was treated with 100 &#x3bc;l of BRIGHT-GLO&#x2122; solution, which had been prepared by adding BRIGHT-GLO&#x2122; buffer to BRIGHT-GLO&#x2122; substrate, and reaction was allowed to proceed for 1 minute at room temperature.</p><p id="p-0120" num="0115">Thereafter, relative light unit (RLU) values were measured with a microplate reader (Perkin Elmer, Wallac Victor X5) capable of measuring luminescence. The results are shown in Table 2 below. Here, two improved long-acting GDF15 fusion proteins were selected based on in vitro GDF15 activity (E<sub>max </sub>of 100%) of the fusion protein (FWT+Fc_hole) including mature GDF15, which was a control.</p><p id="p-0121" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="70pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="3" rowsep="1">TABLE 2</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Changes in sequence of </entry><entry>E<sub>max </sub>(%)</entry><entry/></row><row><entry/><entry>GDF15 in long-acting</entry><entry>[relative to </entry><entry>EC<sub>50 </sub></entry></row><row><entry/><entry>GDF15 fusion protein:</entry><entry>FWT 100%]</entry><entry>(nM)</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><colspec colname="3" colwidth="70pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>&#x394;N2: FWT + Fc_hole</entry><entry>100.0</entry><entry>7.0</entry></row><row><entry/><entry>&#x394;N2, N56C, D103C: </entry><entry>133.3</entry><entry>3.4</entry></row><row><entry/><entry>FM4 + Fc_hole</entry><entry/><entry/></row><row><entry/><entry>&#x394;N2, W32F</entry><entry>51.3</entry><entry>19.4</entry></row><row><entry/><entry>&#x394;N2, W32H</entry><entry>Not active</entry><entry>Not active</entry></row><row><entry/><entry>&#x394;N2, W32Y</entry><entry>Not active</entry><entry>Not active</entry></row><row><entry/><entry>&#x394;N2, Q51H</entry><entry>90.8</entry><entry>24.1</entry></row><row><entry/><entry>&#x394;N2, Q51L</entry><entry>88.6</entry><entry>15.2</entry></row><row><entry/><entry>&#x394;N2, Q51E</entry><entry>41.9</entry><entry>44.2</entry></row><row><entry/><entry>&#x394;N2, Q51N</entry><entry>87.8</entry><entry>14.2</entry></row><row><entry/><entry>&#x394;N2, Q90H</entry><entry>73.2</entry><entry>43.4</entry></row><row><entry/><entry>&#x394;N2, Q90E</entry><entry>10.5</entry><entry>9.3</entry></row><row><entry/><entry>&#x394;N2, Q90K</entry><entry>Not active</entry><entry>Not active</entry></row><row><entry/><entry>&#x394;N2, D93E</entry><entry>87.6</entry><entry>6.5</entry></row><row><entry/><entry>&#x394;N2, D93L</entry><entry>59.1</entry><entry>9.0</entry></row><row><entry/><entry>&#x394;N2, D93N</entry><entry>99.6</entry><entry>22.6</entry></row><row><entry/><entry>&#x394;N2, D93Q</entry><entry>Not active</entry><entry>Not active</entry></row><row><entry/><entry>&#x394;N2, Q60L</entry><entry>96.3</entry><entry>11.9</entry></row><row><entry/><entry>&#x394;N2, Q60N</entry><entry>43.5</entry><entry>7.0</entry></row><row><entry/><entry>&#x394;N2, S64K: FM5 + </entry><entry>147.2</entry><entry>7.7</entry></row><row><entry/><entry>Fc_hole</entry><entry/><entry/></row><row><entry/><entry>&#x394;N2, S64Q</entry><entry>100.0</entry><entry>7.9</entry></row><row><entry/><entry>&#x394;N2, T92S</entry><entry>112.0</entry><entry>14.9</entry></row><row><entry/><entry>&#x394;N2, T92E</entry><entry>12.3</entry><entry>1.1</entry></row><row><entry/><entry>&#x394;N2, S97N</entry><entry>100.2</entry><entry>5.6</entry></row><row><entry/><entry>&#x394;N2, S97Q</entry><entry>117.6</entry><entry>9.2</entry></row><row><entry/><entry>&#x394;N2, Y101F</entry><entry>37.5</entry><entry>31.8</entry></row><row><entry/><entry>&#x394;N2, Y101Q</entry><entry>16.3</entry><entry>12.9</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0122" num="0116">As a result, the two selected long-acting GDF15 fusion proteins were a long-acting GDF15 fusion protein (hereinafter referred to as FM4+Fc_hole) having the mutations &#x394;N2, N56C, and D103C, and a long-acting GDF15 fusion protein (hereinafter referred to as FM5+Fc_hole) having the mutations &#x394;N2 and S64K; and their in vitro GDF15 activity (E<sub>max</sub>) was measured to be 133.3% and 147.2%, respectively. From these results, it was identified that the FM4+Fc_hole and the FM5+Fc_hole had improved in vitro GDF15 activity.</p><heading id="h-0016" level="1">Example 3: Measurement of Activity of Long-Acting GDF15 Fusion Protein (Dimer: FM4+Fc_Hole)</heading><p id="p-0123" num="0117">In GDF15-GDF15 interaction between the long-acting GDF15 fusion proteins, it was identified in Example 2 that the FM4+Fc_hole, to which an additional disulfide bond was introduced, had improved in vitro GDF15 activity. On the basis of these results, to identify importance of the disulfide bond, long-acting GDF15 fusion proteins, which were based on the FM4+Fc_hole and in which asparagine (N), which is the amino acid at position 56 in mature GDF15, and/or aspartic acid (D), which is the amino acid at position 103 in mature GDF15, was substituted with another amino acid, were additionally designed as shown in Table 3 below, and produced in the same manner as in Example 1. Then, in vitro GDF15 activity was evaluated in the same manner as in Example 2.</p><p id="p-0124" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 3</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Designation of</entry><entry>Changes in sequence of </entry><entry>E<sub>max </sub>(%)</entry><entry/></row><row><entry>substance</entry><entry>GDF15 in long-acting </entry><entry>[relative to </entry><entry>EC<sub>50 </sub></entry></row><row><entry>(SEQ ID NO)</entry><entry>GDF15 fusion protein</entry><entry>FWT 100%]</entry><entry>(nM)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="35pt" align="char" char="."/><tbody valign="top"><row><entry>FWT + Fc_hole</entry><entry>&#x394;N2</entry><entry>100.0</entry><entry>5.4</entry></row><row><entry>(SEQ ID NOs: 49 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry>FM4 + Fc_hole</entry><entry>&#x394;N2, N56C, D103C</entry><entry>140.1</entry><entry>3.6</entry></row><row><entry>(SEQ ID NOs: 65 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry>FM4-1 + Fc_hole</entry><entry>&#x394;N2, N56S, D103S</entry><entry>86.4</entry><entry>8.9</entry></row><row><entry>(SEQ ID NOs: 66 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry>FM4-2 + Fc_hole</entry><entry>&#x394;N2, D103L</entry><entry>109.7</entry><entry>10.6</entry></row><row><entry>(SEQ ID NOs: 64 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry>FM4-3 + Fc_hole</entry><entry>&#x394;N2, N56L</entry><entry>34.3</entry><entry>140.1</entry></row><row><entry>(SEQ ID NOs: 53 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0125" num="0118">As a result, as shown in Table 3, it was identified that only the FM4+Fc_hole improved in vitro GDF15 activity (E<sub>max</sub>) as compared with the FWT+Fc_hole (<figref idref="DRAWINGS">FIG. <b>1</b></figref>). From these results, it was identified that introduction of cysteine and resultant introduction of a disulfide bond played an important role in improving in vitro GDF15 activity of the FM4+Fc_hole.</p><heading id="h-0017" level="1">Example 4: Measurement of Activity of Long-Acting GDF15 Fusion Protein (Dimer: FM5+Fc_Hole)</heading><p id="p-0126" num="0119">It was identified in Example 2 that the FM5+Fc_hole, which is an S64K variant of GDF15, had improved in vitro GDF15 activity. On the basis of these results, long-acting GDF15 fusion proteins, which were based on the FM5+Fc_hole and in which serine (S), which is the amino acid at position 64 in mature GDF15 was substituted with another amino acid, were additionally designed as shown in Table 4 below, and produced in the same manner as in Example 1. Then, in vitro GDF15 activity was evaluated in the same manner as in Example 2.</p><p id="p-0127" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 4</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Designation of</entry><entry>Changes in sequence of </entry><entry>E<sub>max </sub>(%)</entry><entry/></row><row><entry>substance</entry><entry>GDF15 in long-acting </entry><entry>[relative to </entry><entry>EC<sub>50 </sub></entry></row><row><entry>(SEQ ID NO)</entry><entry>GDF15 fusion protein</entry><entry>FWT 100%]</entry><entry>(nM)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="35pt" align="char" char="."/><tbody valign="top"><row><entry>FWT + Fc_hole</entry><entry>&#x394;N2</entry><entry>100.0</entry><entry>7.3</entry></row><row><entry>(SEQ ID NOs: 49 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry>FM9 + Fc_hole</entry><entry>&#x394;N2, S64R</entry><entry>123.2</entry><entry>5.0</entry></row><row><entry>(SEQ ID NOs: 57 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry>FM13 + Fc_hole</entry><entry>&#x394;N2, S64N</entry><entry>93.3</entry><entry>9.6</entry></row><row><entry>(SEQ ID NOs: 60 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry>FM14 + Fc_hole</entry><entry>&#x394;N2, S64D</entry><entry>48.2</entry><entry>7.9</entry></row><row><entry>(SEQ ID NOs: 61 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry>FM15 + Fc_hole</entry><entry>&#x394;N2, S64E</entry><entry>41.0</entry><entry>33.6</entry></row><row><entry>(SEQ ID NOs: 62 </entry><entry/><entry/><entry/></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry>FM16 + Fc_hole</entry><entry/><entry/><entry/></row><row><entry>(SEQ ID NOs: 63 </entry><entry>&#x394;N2, S64L</entry><entry>74.7</entry><entry>17.6</entry></row><row><entry>and 43)</entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0128" num="0120">As a result, as shown in Table 4, it was identified that only the FM9+Fc_hole had improved in vitro GDF15 activity (E<sub>max</sub>) as compared with FWT (<figref idref="DRAWINGS">FIG. <b>2</b></figref>).</p><heading id="h-0018" level="1">Example 5: Measurement of Binding Affinity of Long-Acting GDF15 Fusion Proteins (Dimers: FM4+Fc_Hole, FM5+Fc_Hole, and FM9+Fc_Hole)</heading><p id="p-0129" num="0121">The FM4+Fc_hole, the FM5+Fc_hole, and the FM9+Fc_hole, having improved in vitro GDF15 activity, in Examples 3 and 4 were compared in terms of binding affinity for GFRAL and RET which are GDF15 receptors. To measure binding affinity for the GDF15 receptors, a cell-based enzyme-linked immunosorbent assay (ELISA) was performed using the HEK293 cell line overexpressing GFRAL and RET.</p><p id="p-0130" num="0122">Specifically, 1&#xd7;10<sup>5 </sup>HEK293 cells overexpressing GFRAL/RET/SRE-luc were dispensed into each well of a 96-well-plate in DMEM medium containing 10% FBS, and then incubated for 24 hours at 37&#xb0; C. and 5% CO<sub>2</sub>. After 24 hours, the medium was removed from each well of the 96-well-plate. Then, each medium was treated with 4% paraformaldehyde and reaction was allowed to proceed for 20 minutes at room temperature. Paraformaldehyde was removed therefrom. Treatment with 0.6% hydrogen peroxide solution was performed, and reaction was allowed to proceed again for 20 minutes. Then, treatment with 3% bovine serum albumin (BSA)-phosphate buffered saline with Tween 20 (PBST) buffer was performed, and blocking was allowed to proceed for 2 hours.</p><p id="p-0131" num="0123">In addition, the FM4+Fc_hole, the FM5+Fc_hole, or the FM9+Fc_hole was subjected to 2-fold serial dilution, starting from 200 &#x3bc;g/mL, using PBS buffer containing 1% BSA. 100 &#x3bc;l of the FM4+Fc_hole, the FM5+Fc_hole, or the FM9+Fc_hole, each of which was diluted in various concentrations, was applied to a 96-well-plate containing a GFRAL/RET-overexpressing cell line, and reaction was allowed to proceed for 2 hours at room temperature. Then, each well was treated with horseradish peroxidase (HRP)-conjugated anti-human IgG-Fc antibody (Jackson ImmunoResearch #109-035-098), and then developed with 3,3,5,5-tetramethylbenzidine (TMB) buffer (Bio-Rad #172-1066).</p><p id="p-0132" num="0124">Each well was treated with 100 &#x3bc;l of TMB solution, and reaction was allowed to proceed for 10 minutes at room temperature. Then, the reaction was stopped using a 2N sulfuric acid (H<sub>2</sub>SO<sub>4</sub>) reagent. Then, absorbance was measured at 450 nm with a microplate reader (Perkin Elmer, Wallac Victor X5) to evaluate binding capacity, to the GDF15 receptors, of the GDF15 variant in the long-acting GDF15 fusion protein (dimer).</p><p id="p-0133" num="0125">As a result, as illustrated in <figref idref="DRAWINGS">FIG. <b>4</b></figref>, as compared with the FWT+Fc_hole as a control, the FM9+Fc_hole showed remarkably superior binding affinity for the GDF15 receptors, and the FM4+Fc_hole and the FM5+Fc_hole also showed high binding affinity for the GDF15 receptors.</p><heading id="h-0019" level="1">Example 6: Purity Improvement after Purification for Long-Acting GDF15 Fusion Protein (Dimer)</heading><p id="p-0134" num="0126">To improve purification yield, purity, and the like of each long-acting GDF15 fusion protein at the time of producing the same, N-linked glycans were introduced at various positions in GDF15. Presence of N-linked glycans in the GDF15 sequence is known to increase retention time of the corresponding protein in the endoplasmic reticulum and Golgi apparatus during a process of protein secretion, thereby minimizing misfolded products and helping protein expression. Increased retention time has a beneficial effect on folding kinetics and can result in significantly improved heterodimeric (Fc/Fc) knob-in-hole assembly and recovery from mammalian tissue culture.</p><p id="p-0135" num="0127">Evaluation of purity improvement after purification for a substance, obtained by introducing N-linked glycans into a long-acting GDF15 fusion protein, as compared with a dimer of the fusion protein FWT+Fc_hole as a control, was performed in terms of correctly-assembled fusion protein dimer purity using size-exclusion chromatography analysis.</p><p id="p-0136" num="0128">Specifically, long-acting GDF15 fusion proteins, in which N-linked glycans were introduced at various positions in GDF15, were additionally designed. In this regard, variants having increased correctly-assembled fusion protein dimer purity, which was obtained in a case where the variants were produced and subjected to first-step purification in the same manner as in Example 1, as compared with a dimer of the fusion protein FWT+Fc_hole, are shown in Table 6.</p><p id="p-0137" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="56pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 6</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Changes in sequence of </entry><entry>Purity after first-</entry></row><row><entry>Designation of substance</entry><entry>GDF15 in long-acting</entry><entry>step purification</entry></row><row><entry>(SEQ ID NO)</entry><entry>GDF15 fusion protein</entry><entry>(Intact %)</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>FWT + Fc_hole</entry><entry>&#x394;N2</entry><entry>50.9</entry></row><row><entry>(SEQ ID NOs: 49 and 43)</entry><entry/><entry/></row><row><entry>FM1 + Fc_hole</entry><entry>&#x394;N3, WS insertion, G4N, </entry><entry>80.2</entry></row><row><entry>(SEQ ID NOs: 50 and 43)</entry><entry>D5S, H6T</entry><entry/></row><row><entry>FM2 + Fc_hole</entry><entry>&#x394;N3, G4N, D5S, H6T</entry><entry>73.0</entry></row><row><entry>(SEQ ID NOs: 51 and 43)</entry><entry/><entry/></row><row><entry>FM3 + Fc_hole</entry><entry>&#x394;N2, R21N</entry><entry>86.3</entry></row><row><entry>(SEQ ID NOs: 52 and 43)</entry><entry/><entry/></row><row><entry>FM10 + Fc_hole</entry><entry>&#x394;N3, WS insertion, G4N, </entry><entry>65.2</entry></row><row><entry>(SEQ ID NOs: 58 and 43)</entry><entry>D5S, H6T, S64R</entry><entry/></row><row><entry>FM11 + Fc_hole</entry><entry>&#x394;N3, G4N, D5S, H6T, </entry><entry>70.3</entry></row><row><entry>(SEQ ID NOs: 59 and 43)</entry><entry>S64R</entry><entry/></row><row><entry>FM12 + Fc_hole</entry><entry>&#x394;N2, R21N, S64R</entry><entry>82.8</entry></row><row><entry>(SEQ ID NOs: 68 and 43)</entry><entry/><entry/></row><row><entry>B13a/B13b</entry><entry>&#x394;N2, D5T</entry><entry>75.8</entry></row><row><entry>(see sequences in U.S. Pat.</entry><entry/><entry/></row><row><entry>No. 9,920,118)</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0138" num="0129">As a result, it was identified that the FWT+Fc_hole had correctly-assembled fusion protein dimer purity after first-step purification of 50.9%, whereas the FM1+Fc_hole, the FM2+Fc_hole, the FM3+Fc_hole, the FM10+Fc_hole, the FM11+Fc_hole, and the FM12+Fc_hole, in each of which N-linked glycans were introduced into GDF15, had improved, correctly-assembled fusion protein dimer purity of 80.2%, 73.0%, 86.3%, 65.2%, and 70.3%, respectively.</p><p id="p-0139" num="0130">In addition, the NGM Biopharmaceuticals, Inc.'s fusion protein dimer (B13a/B13b (into which N-linked glycans are introduced) in U.S. Pat. No. 9,920,118 was measured to have purity of 75.8%.</p><heading id="h-0020" level="1">Example 7: Evaluation of Activity of Long-Acting GDF15 Fusion Proteins (Dimers: FM10+Fc_Hole, FM11+Fc_Hole, and FM12+Fc_Hole)</heading><p id="p-0140" num="0131">Using the FM1+Fc_hole, the FM2+Fc_hole, and the FM3+Fc_hole, in each of which N-linked glycans were introduced at various positions in GDF15, as controls, the FM10+Fc_hole, the FM11+Fc_hole, and the FM12+Fc_hole were evaluated, in terms of GDF15 activity, in the same manner as in Example 2. The results are shown in Table 7.</p><p id="p-0141" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="84pt" align="left"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 7</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Designation of</entry><entry>Changes in sequence of </entry><entry/><entry/></row><row><entry>substance</entry><entry>GDF15 in long-acting </entry><entry>E<sub>max</sub></entry><entry>EC<sub>50 </sub></entry></row><row><entry>(SEQ ID NO)</entry><entry>GDF15 fusion protein</entry><entry>(%)</entry><entry>(nM)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>FM1 + Fc_hole</entry><entry>&#x394;N3, WS insertion, G4N, </entry><entry>100.0</entry><entry>1.7</entry></row><row><entry>(SEQ ID NOs: 50 and</entry><entry>D5S, H6T</entry><entry/><entry/></row><row><entry>43)</entry><entry/><entry/><entry/></row><row><entry>FM2 + Fc_hole</entry><entry>&#x394;N3, G4N, D5S, H6T</entry><entry>100.0</entry><entry>3.9</entry></row><row><entry>(SEQ ID NOs: 51 and</entry><entry/><entry/><entry/></row><row><entry>43)</entry><entry/><entry/><entry/></row><row><entry>FM3 + Fc_hole</entry><entry>&#x394;N2, R21N</entry><entry>100.0</entry><entry>3.3</entry></row><row><entry>(SEQ ID NOs: 52 and</entry><entry/><entry/><entry/></row><row><entry>43)</entry><entry/><entry/><entry/></row><row><entry>FM10 + Fc_hole</entry><entry>&#x394;N3, WS insertion, G4N, </entry><entry>267.0</entry><entry>2.3</entry></row><row><entry>(SEQ ID NOs: 58 and</entry><entry>D5S, H6T, S64R</entry><entry/><entry/></row><row><entry>43)</entry><entry/><entry/><entry/></row><row><entry>FM11 + Fc_hole</entry><entry>&#x394;N3, G4N, D5S, H6T, </entry><entry>269.5</entry><entry>2.9</entry></row><row><entry>(SEQ ID NOs: 59 and</entry><entry>S64R</entry><entry/><entry/></row><row><entry>43)</entry><entry/><entry/><entry/></row><row><entry>FM12 + Fc_hole</entry><entry>&#x394;N2, R21N, S64R</entry><entry>221.4</entry><entry>5.9</entry></row><row><entry>(SEQ ID NOs: 68 and</entry><entry/><entry/><entry/></row><row><entry>43)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0142" num="0132">As a result, as shown in Table 7, it was identified that the FM10+Fc_hole, the FM11+Fc_hole, and the FM12+Fc_hole had improved GDF15 activity (E<sub>max</sub>) as compared with the FM1+Fc_hole, the FM2+Fc_hole, and the FM3+Fc_hole (<figref idref="DRAWINGS">FIGS. <b>5</b> to <b>7</b></figref>).</p><heading id="h-0021" level="1">Example 8: Measurement of Binding Affinity of Long-Acting GDF15 Fusion Proteins (Dimers: FM10+Fc_Hole and FM11+Fc_Hole)</heading><p id="p-0143" num="0133">Binding affinity of the FM10+Fc_hole or the FM11+Fc_hole for the GDF15 receptors, GFRAL and RET, were compared and evaluated in the same manner as in Example 5. As a result, as illustrated in <figref idref="DRAWINGS">FIG. <b>6</b></figref>, remarkably superior affinity for the GDF15 receptors was measured in the FM10+Fc_hole and the FM11+Fc_hole as compared with the FWT+Fc_hole as a control (<figref idref="DRAWINGS">FIG. <b>8</b></figref>).</p><heading id="h-0022" level="1">Example 9: Production of Long-Acting GDF15 Fusion Proteins (Dimers: FM6+Fc_Hole, FM7+Fc_Hole, and FM8+Fc_Hole)</heading><p id="p-0144" num="0134">Based on the results of Examples 1 to 8, long-acting GDF15 fusion proteins, in which the amino acids at positions 21 and/or 64 were substituted and N-linked glycans were introduced at various positions in GDF15, were additionally designed. In this regard, variants having increased correctly-assembled fusion protein dimer purity, which was obtained in a case where the variants were produced and subjected to first-step purification in the same manner as in Example 1, as compared with a dimer of the fusion protein FWT+Fc_hole, are shown in Table 8.</p><p id="p-0145" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="70pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 8</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>Designation of</entry><entry>Changes in sequence of </entry><entry>Purity after first-step</entry></row><row><entry>substance</entry><entry>GDF15 in long-acting </entry><entry>purification</entry></row><row><entry>(SEQ ID NO)</entry><entry>GDF15 fusion protein</entry><entry>(Intact %)</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>FWT + Fc_hole</entry><entry>&#x394;N2</entry><entry>50.9</entry></row><row><entry>(SEQ ID NOs: 49 and</entry><entry/><entry/></row><row><entry>43)</entry><entry/><entry/></row><row><entry>FM6 + Fc_hole</entry><entry>&#x394;N3, WS insertion, </entry><entry>66.4</entry></row><row><entry>(SEQ ID NOs: 55 and</entry><entry>G4N, D5S, H6T, S64K</entry><entry/></row><row><entry>43)</entry><entry/><entry/></row><row><entry>FM7 + Fc_hole</entry><entry>&#x394;N3, G4N, D5S, H6T, </entry><entry>N/A</entry></row><row><entry>(SEQ ID NOs: 56 and</entry><entry>S64K</entry><entry/></row><row><entry>43)</entry><entry/><entry/></row><row><entry>FM8 + Fc_hole</entry><entry>&#x394;N2, R21N, S64K</entry><entry>N/A</entry></row><row><entry>(SEQ ID NOs: 67 and</entry><entry/><entry/></row><row><entry>43)</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0023" level="1">Example 10: Optimization of Fusion Carrier and Linker for Long-Acting GDF15 Fusion Proteins</heading><p id="p-0146" num="0135">In order to conduct optimization studies of a fusion carrier and a linker for the two variants (FM9+Fc_hole and FM11+Fc_hole) showing excellent activity and purity improvement after purification, long-acting GDF15 fusion proteins, in which fusion carriers (SEQ ID NOs: 46 and 47) and various linkers (SEQ ID NOs: 92, 93, 94, 95, 96, and 97) were introduced into respective GDF15 sequences to minimize an effector function, were additionally designed and are shown in Table 9.</p><p id="p-0147" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="91pt" align="left"/><colspec colname="3" colwidth="133pt" align="left"/><colspec colname="4" colwidth="84pt" align="left"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE&#x2003;9</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Designation&#x2003;of</entry><entry>Changes&#x2003;in</entry><entry/><entry/></row><row><entry>substance</entry><entry>sequence</entry><entry/><entry/></row><row><entry>(SEQ&#x2003;ID&#x2003;NO)</entry><entry>of&#x2003;GDF15</entry><entry>Fusion&#x2003;carrier</entry><entry>Linker&#x2003;sequence</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>FM9-1&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(G4S)<sub>3</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;98</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;28)</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;92)</entry></row><row><entry>and&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-2&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(G4S)<sub>5</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;99</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;28)</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;93)</entry></row><row><entry>and&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-3&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(G4S)<sub>7</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;100</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;28)</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;94)</entry></row><row><entry>and&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-4&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(EEEA)<sub>6</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;101</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;28)</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;95)</entry></row><row><entry>and&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-5&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GSGGSS(PT)<sub>10</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;102</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;28)</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;96)</entry></row><row><entry>and&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-6&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(EAAAK)<sub>5</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;103</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;28)</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;97)</entry></row><row><entry>and&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-1&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,&#x2003;H6T,</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(G4S)<sub>3</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;104</entry><entry>S64R&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;92)</entry></row><row><entry>and&#x2003;47)</entry><entry>30)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-2&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,&#x2003;H6T,</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(G4S)<sub>5</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;105</entry><entry>S64R&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;93)</entry></row><row><entry>and&#x2003;47)</entry><entry>30)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-3&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,&#x2003;H6T,</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(G4S)<sub>7</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;106</entry><entry>S64R&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;94)</entry></row><row><entry>and&#x2003;47)</entry><entry>30)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-4&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,&#x2003;H6T,</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(EEEA)<sub>6</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;107</entry><entry>S64R&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;95)</entry></row><row><entry>and&#x2003;47)</entry><entry>30)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-5&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,&#x2003;H6T,</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GSGGSS(PT)<sub>10</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;108</entry><entry>S64R&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;96)</entry></row><row><entry>and&#x2003;47)</entry><entry>30)</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-6&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,&#x2003;H6T,</entry><entry>IgG1&#x2003;Fc_knob&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>GS(EAAAK)<sub>5</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;109</entry><entry>S64R&#x2003;(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;97)</entry></row><row><entry>and&#x2003;47)</entry><entry>30)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0024" level="1">Example 10.1: Expression and Purification of Optimized Long-Acting GDF15 Fusion Proteins (Dimers)</heading><p id="p-0148" num="0136">The optimized long-acting GDF15 fusion proteins as shown in Table 9 were produced and subjected to first-step purification in the same manner as in Example 1. To obtain a high-purity long-acting GDF15 fusion protein, a pool obtained by completing the first-step purification was subjected to second-step ion exchange (IEX) purification using anion exchange (AEX) resin and cation exchange (CEX) resin.</p><p id="p-0149" num="0137">Specifically, for the anion exchange (AEX), the pool that had undergone the first step was loaded onto POROS HQ&#x2122; 50 &#x3bc;M Strong Anion Exchange Resin (Thermo Fisher Scientific) equilibrated with 1&#xd7;PBS (pH 7.4), to induce binding. After completion of the binding between the first polypeptide and the second polypeptide, the POROS HQ&#x2122; 50 &#x3bc;M Strong Anion Exchange Resin was washed with 1&#xd7;PBS (pH 7.4), and then elution was performed by concentration gradient using 50 mM Tris-HCl (pH 8.0) solution with 1 M sodium chloride, to obtain a final substance. Fractions meeting a criterion for purity of 95% or higher were pooled using size exclusion chromatography analysis.</p><p id="p-0150" num="0138">In addition, for the cation exchange (CEX), the pool that had undergone the first step was subjected to pH adjustment depending on isoelectric points, and then loaded onto POROS XS&#x2122; Strong Cation Exchange Resin (Thermo Fisher Scientific) equilibrated with 20 mM sodium phosphate (pH 6.5) solution, to induce binding. After completion of the binding between the first polypeptide and the second polypeptide, the POROS XS&#x2122; Strong Cation Exchange Resin was washed with 20 mM sodium phosphate (pH 6.5) solution, and then elution was performed by concentration gradient using 20 mM sodium phosphate (pH 6.5) solution with 1 M sodium chloride, to obtain a final substance. Fractions meeting a criterion for purity of 95% or higher were pooled using size exclusion chromatography analysis.</p><heading id="h-0025" level="1">Example 10.2: Evaluation of Activity of Optimized Long-Acting GDF15 Fusion Proteins (Dimers)</heading><p id="p-0151" num="0139">The two variants (FM9+Fc_hole and FM11+Fc_hole) showing excellent activity and purity improvement after purification were compared and evaluated in terms of activity depending on linker type and length. Activity of the respective long-acting GDF15 fusion proteins was evaluated in the same manner as in Example 2, and the results are shown in Table 10. Here, the long-acting GDF15 fusion proteins were compared, in terms of activity depending on GDF15 sequence, and linker type and length, based on in vitro GDF15 activity (E<sub>max </sub>of 100%) of the FM9-6+Fc_hole.</p><p id="p-0152" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="84pt" align="left"/><colspec colname="4" colwidth="70pt" align="left"/><colspec colname="5" colwidth="35pt" align="left"/><colspec colname="6" colwidth="28pt" align="left"/><thead><row><entry namest="1" nameend="6" rowsep="1">TABLE&#x2003;10</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>Designation&#x2003;of</entry><entry>Changes&#x2003;in</entry><entry/><entry/><entry/><entry/></row><row><entry>substance</entry><entry>sequence&#x2003;of</entry><entry/><entry/><entry>E<sub>max</sub></entry><entry>EC<sub>50</sub></entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NO)</entry><entry>GDF15</entry><entry>Fusion&#x2003;carrier</entry><entry>Linker&#x2003;sequence</entry><entry>(%)</entry><entry>(nM)</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>FM9-1&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(G4S)<sub>3</sub></entry><entry>&#x2003;97.6</entry><entry>&#x2003;9.0</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;98</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;92)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>28)</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-2&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(G4S)<sub>5</sub></entry><entry>110.8</entry><entry>&#x2003;9.5</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;99</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;93)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>28)</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-3&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(G4S)<sub>7</sub></entry><entry>&#x2003;95.6</entry><entry>&#x2003;9.3</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;100</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;94)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>28)</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-4&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(EEEA)<sub>6</sub></entry><entry>127.6</entry><entry>23.6</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;101</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;95)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>28)</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-5&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GSGGSS(PT)<sub>10</sub></entry><entry>100.0</entry><entry>&#x2003;5.3</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;102</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;96)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>28)</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM9-6&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N2,&#x2003;S64R</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(EAAAK)<sub>6</sub></entry><entry>100.0</entry><entry>&#x2003;6.3</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;103</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;97)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>28)</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-1&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(G4S)<sub>3</sub></entry><entry>&#x2003;65.6</entry><entry>&#x2003;9.7</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;104</entry><entry>H6T,&#x2003;S64R</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;92)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry>30)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-2&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(G4S)<sub>5</sub></entry><entry>&#x2003;79.4</entry><entry>&#x2003;7.7</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;105</entry><entry>H6T,&#x2003;S64R</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;93)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry>30)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-3&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(G4S)<sub>7</sub></entry><entry>&#x2003;81.0</entry><entry>&#x2003;7.8</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;106</entry><entry>H6T,&#x2003;S64R</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;94)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry>30)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-4&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(EEEA)<sub>6</sub></entry><entry>104.8</entry><entry>45.4</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;107</entry><entry>H6T,&#x2003;S64R</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;95)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry>30)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-5&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GSGGSS(PT)<sub>10</sub></entry><entry>&#x2003;68.2</entry><entry>&#x2003;5.1</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;108</entry><entry>H6T,&#x2003;S64R</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;96)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry>30)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>FM11-6&#x2003;+&#x2003;Fc_hole</entry><entry>&#x394;N3,&#x2003;G4N,&#x2003;D5S,</entry><entry>IgG1&#x2003;Fc_knob</entry><entry>GS(EAAAK)<sub>5</sub></entry><entry>&#x2003;80.3</entry><entry>&#x2003;6.8</entry></row><row><entry>(SEQ&#x2003;ID&#x2003;NOs:&#x2003;109</entry><entry>H6T,&#x2003;S64R</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;97)</entry><entry/><entry/></row><row><entry>and&#x2003;47)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:</entry><entry>IgG1&#x2003;Fc_hole</entry><entry/><entry/><entry/></row><row><entry/><entry>30)</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0153" num="0140">As a result, as shown in Table 10, it was identified that the respective long-acting GDF15 fusion proteins exhibited similar activity except those in which the linker GS(EEEA)<sub>6 </sub>(SEQ ID NO: 95) was used, and the long-acting GDF15 fusion proteins (FM9-4+Fc_hole and FM11-4+Fc_hole), in which linker GS(EEEA)<sub>6 </sub>(SEQ ID NO: 95) was used, exhibited relatively low EC50 value and high E<sub>max </sub>value (<figref idref="DRAWINGS">FIGS. <b>9</b> and <b>10</b></figref>).</p><heading id="h-0026" level="1">Example 10.3: Pharmacokinetic Evaluation of Optimized Long-Acting GDF15 Fusion Proteins (Dimers)</heading><p id="p-0154" num="0141">On the day of drug treatment, six-week-old male C57BL/6 mice purchased from Orient BIO (Korea) were divided into groups (n=3 per blood collection time point) so that each group had a similar average value of body weight, and then the FM9-4+Fc_hole, the FM9-6+Fc_hole, the FM11-4+Fc_hole, and the FM11-6+Fc_hole were respectively administered subcutaneously once at a dose of 1 mg/kg. Blood samples were respectively collected 4, 24, 48, 72, 96, 120, 168, and 240 hours after the administration. A concentration of each long-acting GDF15 fusion protein (dimer) in mouse blood was measured using an immunoassay method. Based on the measured concentration values, pharmacokinetic parameter results were calculated for the respective long-acting GDF15 fusion proteins (dimers) and are shown in Table 11 below.</p><p id="p-0155" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="42pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><thead><row><entry namest="1" nameend="7" rowsep="1">TABLE 11</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry>Designation of</entry><entry/><entry/><entry/><entry/><entry/><entry/></row><row><entry>substance</entry><entry>C<sub>max</sub></entry><entry>T<sub>max</sub></entry><entry>CL/F</entry><entry>Vd/F</entry><entry>AUC<sub>last</sub></entry><entry>T<sub>1/2, app</sub></entry></row><row><entry>(SEQ ID NO)</entry><entry>(ng/mL)</entry><entry>(hr)</entry><entry>(mL/hr/kg)</entry><entry>(mL/kg)</entry><entry>(ng &#xb7; hr/mL)</entry><entry>(hr)</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="28pt" align="char" char="."/><colspec colname="3" colwidth="21pt" align="char" char="."/><colspec colname="4" colwidth="42pt" align="char" char="."/><colspec colname="5" colwidth="28pt" align="char" char="."/><colspec colname="6" colwidth="42pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="char" char="."/><tbody valign="top"><row><entry>FM9-4 + Fc_hole</entry><entry>8421.37</entry><entry>24</entry><entry>1.30</entry><entry>69.31</entry><entry>750497.02</entry><entry>36.84</entry></row><row><entry>(SEQ ID NOs: 101</entry></row><row><entry>and 47)</entry></row><row><entry>FM9-6 + Fc_hole</entry><entry>7581.92</entry><entry>24</entry><entry>0.91</entry><entry>111.02</entry><entry>939308.72</entry><entry>84.28</entry></row><row><entry>(SEQ ID NOs: 103</entry></row><row><entry>and 47)</entry></row><row><entry>FM11-4 + Fc_hole</entry><entry>7200.02</entry><entry>24</entry><entry>1.41</entry><entry>82.63</entry><entry>690213.08</entry><entry>40.61</entry></row><row><entry>(SEQ ID NOs: 107</entry></row><row><entry>and 47)</entry></row><row><entry>FM11-6 + Fc_hole</entry><entry>1547.77</entry><entry>24</entry><entry>8.43</entry><entry>314.10</entry><entry>116433.94</entry><entry>25.84</entry></row><row><entry>(SEQ ID NOs: 109</entry></row><row><entry>and 47)</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0027" level="1">Example 10.4: Evaluation of Anti-Obesity Effect of Optimized Long-Acting GDF15 Fusion Proteins (Dimers), Depending on Different Linker Types, in Diet-Induced Obese (DIO) Mice by Repeated Administration</heading><p id="p-0156" num="0142">Diet-induced obese (DIO) mice which have been induced by feeding a high-fat diet in mice, and are characterized by obesity, hyperglycemia, and insulin resistance. The DIO mice (Taconic, USA) which had been fed a high fat diet (60 kcal % fat, Research Diets, Cat #D12492, USA) in C57BL/6N mice for 8 weeks were purchased from Raon Bio (Animal Inc., Republic of Korea). After the arrival, these animals were additionally fed by the high-fat diet (60% fat) for 5 weeks, and then used in this study. On the day before the dosing start, the animals were divided into groups (n=6 per group) based on mean body weight of individual mice, and then FM9-4+Fc_hole, FM9-6+Fc_hole, FM11-4+Fc_hole, and FM11-6+Fc_hole were administered subcutaneously at 2-day interval (Q2D) for a total of 4 weeks at a dose of 10 nmol/kg, respectively. As reference articles, B13a/B13b (U.S. Pat. No. 9,920,118) at 10 nmol/kg and semaglutide at 30 nmol/kg were administered subcutaneously at 2-day interval (Q2D) for a total of 4 weeks. For vehicle treatment, Dulbecco's phosphate buffered saline (DPBS; Gibco, USA) was administered subcutaneously at 2-day interval (Q2D). Body weight was measured every two days from the first day of drug treatment to Day 28, and the results were shown in Table 12 below.</p><p id="p-0157" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="126pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 12</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Dose</entry><entry>Change of body weight (%) vs. Day 0</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry>Group</entry><entry>(nmol/kg)</entry><entry>Maximal efficacy</entry><entry>Efficacy on Day 27</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="63pt" align="char" char="."/><tbody valign="top"><row><entry>Vehicle</entry><entry>&#x2014;</entry><entry>&#x2014;</entry><entry>4.44</entry></row><row><entry>FM9-4 + Fc_hole</entry><entry>10</entry><entry>&#x2212;20.67 (on Day 27)</entry><entry>&#x2212;20.67</entry></row><row><entry>(SEQ ID NOs: 101 </entry><entry/><entry/><entry/></row><row><entry>and 47)</entry><entry/><entry/><entry/></row><row><entry>FM9-6 + Fc_hole</entry><entry>10</entry><entry>&#x2212;19.93 (on Day 27)</entry><entry>&#x2212;19.93</entry></row><row><entry>(SEQ ID NOs: 103 </entry><entry/><entry/><entry/></row><row><entry>and 47)</entry><entry/><entry/><entry/></row><row><entry>FM11-4 + Fc_hole</entry><entry>10</entry><entry>&#x2212;22.11 (on Day 27)</entry><entry>&#x2212;22.11</entry></row><row><entry>(SEQ ID NOs: 107 </entry><entry/><entry/><entry/></row><row><entry>and 47)</entry><entry/><entry/><entry/></row><row><entry>FM11-6 + Fc_hole</entry><entry>10</entry><entry>&#x2212;11.63 (on Day 22)</entry><entry>&#x2212;9.93</entry></row><row><entry>(SEQ ID NOs: 109 </entry><entry/><entry/><entry/></row><row><entry>and 47)</entry><entry/><entry/><entry/></row><row><entry>B13a/B13b</entry><entry>10</entry><entry>&#x2212;6.18 (on Day 8)</entry><entry>0.60</entry></row><row><entry>Semaglutide</entry><entry>30</entry><entry>&#x2212;19.20 (on Day 22)</entry><entry>&#x2212;16.41</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0158" num="0143">As a result, it was confirmed that all test articles with different linker types (FM9-4+Fc_hole, FM9-6+Fc_hole, FM11-4+Fc_hole, and FM11-6+Fc_hole) demonstrated a marked body weight loss effect, compared to B13a/B13b of 10 nmol/kg, as a reference drug. In addition, three test articles, FM9-4+Fc_hole, FM9-6+Fc_hole, and FM11-4+Fc_hole, showed a body weight reduction effect similar to semaglutide, 30 nmol/kg-treated group (<figref idref="DRAWINGS">FIG. <b>11</b></figref>).</p><heading id="h-0028" level="1">Example 10.5: Evaluation of Anti-Obesity Effect of Optimized Long-Acting GDF15 Fusion Proteins (Dimers) in Diet-Induced Obese Mice by Single Administration</heading><p id="p-0159" num="0144">Male C57BL/6N mice at 6-week-old were purchased from Orient Bio (via Hallym Lab. Animal Inc., Republic of Korea). After the arrival, C57BL/6N mice were induced DIO by feeding with a high-fat diet (60 kcal % fat, Research Diets, Cat #D12492, USA) for a total of 13 weeks. On the day before the dosing start, the animals were divided into groups (n=6 per group) based on mean body weight of individual mice, and then FM9-6+Fc_hole of 1, 3, 10, and 30 nmol/kg was administered subcutaneously once. As a reference article, semaglutide of 30 nmol/kg was administered subcutaneously once. For vehicle treatment, Dulbecco's phosphate buffered saline (DPBS; Gibco, USA) was administered subcutaneously. A body weight was measured daily from the day of drug treatment to Day 42, and the results are shown in Table 13 below.</p><p id="p-0160" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="126pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 13</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Dose</entry><entry>Change of body weight (%) vs. Day 0</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="63pt" align="center"/><tbody valign="top"><row><entry>Group</entry><entry>(nmol/kg)</entry><entry>Maximal efficacy</entry><entry>Efficacy on Day 38</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="63pt" align="char" char="."/><tbody valign="top"><row><entry>Vehicle</entry><entry>&#x2014;</entry><entry>&#x2014;</entry><entry>10.02</entry></row><row><entry>FM9-6 + Fc_hole</entry><entry>1</entry><entry>&#x2002;&#x2212;6.54 (on Day 10)</entry><entry>3.10</entry></row><row><entry>FM9-6 + Fc_hole</entry><entry>3</entry><entry>&#x2002;&#x2212;9.74 (on Day 15)</entry><entry>3.23</entry></row><row><entry>FM9-6 + Fc_hole</entry><entry>10</entry><entry>&#x2212;13.08 (on Day 18)</entry><entry>0.63</entry></row><row><entry>FM9-6 + Fc_hole</entry><entry>30</entry><entry>&#x2212;14.39 (on Day 18)</entry><entry>&#x2212;5.51</entry></row><row><entry>Semaglutide</entry><entry>30</entry><entry>&#x2212;8.38 (on Day 2)</entry><entry>7.33</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0161" num="0145">As a result, in terms of body weight loss effect by single administration, the semaglutide, 30 nmol/kg treated group, as a reference article, demonstrated a pharmacologic effect lasting for 2 days, whereas the single administration of FM9-6+Fc_hole of 1, 3, 10, and 30 nmol/kg was confirmed that anti-obesity effect lasted for 10 days, 15 days, 18 days, and 18 days, respectively for each doses (<figref idref="DRAWINGS">FIG. <b>12</b></figref>).</p><heading id="h-0029" level="1">Example 10.6: Evaluation of Anti-Obesity Effect of Optimized Long-Acting GDF15 Fusion Proteins (Dimers) in Ob/Ob Mice by Repeated Administration</heading><p id="p-0162" num="0146">ob/ob mice are genetically deficient in leptin gene and are characterized by hyperglycemia, insulin resistance, hyperorexia, and obesity. Male ob/ob mice at 5-week-old (Jackson Laboratory, USA) were purchased from Raon Bio (Animal Inc., Republic of Korea). The mice were acclimatized for 4 weeks with normal chow diet (Teklad Certified Irradiated Global 18% Protein Rodent Diet, 2918C, Harlan Co., USA) and drug treatment was initiated at 9-week-old. On the day before the dosing start, the animals were divided into groups (n=6 per group) based on mean body weight and random blood glucose via tail vein of individual mice. Then, the FM9-6+Fc_hole of 0.1, 1, and 3 nmol/kg, and semaglutide of 10 nmol/kg were administered subcutaneously at 3-day interval (Q3D) a total of 10 times, and body weight and food intake were measured every day or every 3 days during experimental period (Day 1- Day 29), respectively. For vehicle treatment, Dulbecco's phosphate buffered saline (DPBS; Gibco, USA) was administered.</p><p id="p-0163" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="126pt" align="center"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 14</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Dose</entry><entry>Change of body weight (%) vs. ob/ob control</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="70pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><tbody valign="top"><row><entry>Group</entry><entry>(nmol/kg)</entry><entry>Maximal efficacy</entry><entry>Efficacy on Day 29</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Vehicle</entry><entry>&#x2014;</entry><entry>&#x2014;</entry><entry>&#x2014;</entry></row><row><entry>FM9-6 + Fc_hole</entry><entry>0.1</entry><entry>&#x2212;10.58 (on Day 28)</entry><entry>&#x2212;9.98</entry></row><row><entry>FM9-6 + Fc_hole</entry><entry>1</entry><entry>&#x2212;21.49 (on Day 29)</entry><entry>&#x2212;21.49</entry></row><row><entry>FM9-6 + Fc_hole</entry><entry>3</entry><entry>&#x2212;19.99 (on Day 29)</entry><entry>&#x2212;19.99</entry></row><row><entry>Semaglutide</entry><entry>10</entry><entry>&#x2212;10.04 (on Day 25)</entry><entry>&#x2212;6.88</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0164" num="0147">As a result, it was confirmed that FM9-6+Fc_hole manifested body weight loss effect in a dose-dependent manner. FM9-6+Fc_hole, 0.1 nmol/kg treated group showed significant reduction in body weight similar to semaglutide, 10 nmol/kg treated group. FM9-6+Fc_hole of 1 nmol/kg or more demonstrated the maximal efficacy in ob/ob mice (<figref idref="DRAWINGS">FIG. <b>13</b></figref>).</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002460A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A growth differentiation factor-15 (GDF15) variant represented by Formula (I):<claim-text><br/><?in-line-formulae description="In-line Formulae" end="lead"?>N-terminal extension domain-core domain&#x2003;&#x2003;(I)<?in-line-formulae description="In-line Formulae" end="tail"?></claim-text><claim-text>in Formula (I),</claim-text><claim-text>- is a bond;</claim-text><claim-text>the N-terminal extension domain is a polypeptide consisting of any one amino acid sequence of SEQ ID NOs: 3 to 5; and</claim-text><claim-text>the core domain is a polypeptide of SEQ ID NO: 20, or a polypeptide derived from SEQ ID NO: 20 in which any one amino acid selected from the group consisting of amino acids at positions 15, 50, 58, 97, and combinations thereof in the amino acid sequence of SEQ ID NO: 20 is substituted with another amino acid;</claim-text><claim-text>wherein arginine (R), which is the amino acid at position 15 with reference to SEQ ID NO: 20, is substituted with alanine (A), aspartic acid (D), asparagine (N), cysteine (C), glutamic acid (E), glutamine (Q), glycine (G), histidine (H), isoleucine (I), leucine (L), lysine (K), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y), or valine (V),</claim-text><claim-text>asparagine (N), which is the amino acid at position 50 in the amino acid sequence of SEQ ID NO: 20, is substituted with alanine, arginine (R), aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine,</claim-text><claim-text>serine (S), which is the amino acid at position 58 in the amino acid sequence of SEQ ID NO: 20, is substituted with alanine, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, or valine, and</claim-text><claim-text>aspartic acid (D), which is the amino acid at position 97 in the amino acid sequence of SEQ ID NO: 20, is substituted with alanine, arginine, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the core domain includes any one variation selected from the group consisting of the following variations (1) to (6):<claim-text>(1) a variation in which arginine (R), which is the amino acid at position 15 in the amino acid sequence of SEQ ID NO: 20, is substituted with asparagine (N);</claim-text><claim-text>(2) a variation in which asparagine (N), which is the amino acid at position 50 in the amino acid sequence of SEQ ID NO: 20, is substituted with leucine (L);</claim-text><claim-text>(3) a variation in which serine (S), which is the amino acid at position 58 in the amino acid sequence of SEQ ID NO: 20, is substituted with lysine (K), arginine (R), asparagine (N), aspartic acid (D), glutamic acid (E), cysteine (C), or leucine (L);</claim-text><claim-text>(4) a variation in which aspartic acid (D), which is the amino acid at position 97 in the amino acid sequence of SEQ ID NO: 20, is substituted with leucine (L);</claim-text><claim-text>(5) a variation in which asparagine (N), which is the amino acid at position 50 in the amino acid sequence of SEQ ID NO: 20, and aspartic acid (D), which is the amino acid at position 97 in the amino acid sequence of SEQ ID NO: 20, are each substituted with cysteine (C) or serine (S); and</claim-text><claim-text>(6) a variation in which arginine (R), which is the amino acid at position 15 in the amino acid sequence of SEQ ID NO: 20, is substituted with asparagine (N), and serine (S), which is the amino acid at position 58 in the amino acid sequence of SEQ ID NO: 20, is substituted with lysine (K) or arginine (R).</claim-text></claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The GDF15 variant of <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein the core domain consists of any one amino acid sequence selected from SEQ ID NOs: 6 to 19.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the GDF15 variant includes the N-terminal extension domain consisting of an amino acid sequence of SEQ ID NO: 3 and the core domain consisting of an amino acid sequence of SEQ ID NO: 8, 9, or 20.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the GDF15 variant includes the N-terminal extension domain consisting of an amino acid sequence of SEQ ID NO: 4 and the core domain consisting of an amino acid sequence of SEQ ID NO: 8, 9, or 20.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the GDF15 variant includes the N-terminal extension domain consisting of an amino acid sequence of SEQ ID NO: 5 and the core domain consisting of any one amino acid sequence selected from SEQ ID NO: 6 to 19.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the GDF15 variant consists of any one amino acid sequence selected from SEQ ID NOs: 21 to 39.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. A long-acting growth differentiation factor-15 (GDF15) fusion protein, in which the GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref> is bound to human IgG Fc or a variant thereof,<claim-text>wherein the human IgG Fc or the variant thereof comprises<claim-text>a first polypeptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 42, 44, and 46; and</claim-text><claim-text>a second polypeptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 43, 45, and 47; and</claim-text></claim-text><claim-text>wherein the C-terminus of the first polypeptide of the IgG Fc or the variant thereof or the C-terminus of the second polypeptide of the IgG Fc or a variant thereof, is bound to the N-terminus of the GDF15 variant.</claim-text></claim-text></claim><claim id="CLM-09-10" num="09-10"><claim-text><b>9</b>.-<b>10</b>. (canceled)</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The long-acting GDF15 fusion protein of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein the GDF15 variant is bound to the IgG Fc or the variant thereof via a linker.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The long-acting GDF15 fusion protein of <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein the linker is (G4S)n, GS(G4S)n, GS(EEEA)n, (EEEA)n, GS(EAAAK)n, (EAAAK)n, or GSGGSS(PT)n, where n is an integer of 1 to 10.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The long-acting GDF15 fusion protein of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the linker is</claim-text><claim-text><tables id="TABLE-US-00015" num="00015"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="196pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;48)</entry></row><row><entry/><entry>GGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;92)</entry></row><row><entry/><entry>GSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;93)</entry></row><row><entry/><entry>GSGGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;94)</entry></row><row><entry/><entry>GSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;95)</entry></row><row><entry/><entry>GSEEEAEEEAEEEAEEEAEEEAEEEA,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;96)</entry></row><row><entry/><entry>GSGGSSPTPTPTPTPTPTPTPTPTPT,</entry></row><row><entry/><entry>or</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;97)</entry></row><row><entry/><entry>GSEAAAKEAAAKEAAAKEAAAKEAAAK.</entry></row></tbody></tgroup></table></tables></claim-text></claim><claim id="CLM-14-15" num="14-15"><claim-text><b>14</b>.-<b>15</b>. (canceled)</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The long-acting GDF15 fusion protein of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein the GDF15 variant includes at least one N-linked glycan.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The long-acting GDF15 fusion protein of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein<claim-text>the GDF15 variant comprises any one amino acid sequence selected from the group consisting of SEQ ID NOs: 21 to 39.</claim-text></claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. A fusion protein dimer, comprising:<claim-text>two of the long-acting GDF15 fusion protein of <claim-ref idref="CLM-00008">claim 8</claim-ref>.</claim-text></claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. An isolated nucleic acid molecule, encoding the GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref>, or a long-acting GDF15 fusion protein in which the GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref> is bound to human IgG Fc or a variant thereof.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. An expression vector, comprising:<claim-text>the nucleic acid molecule of <claim-ref idref="CLM-00019">claim 19</claim-ref>.</claim-text></claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. A host cell, comprising:<claim-text>the expression vector of <claim-ref idref="CLM-00020">claim 20</claim-ref>.</claim-text></claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. A pharmaceutical composition comprising as an active ingredient:<claim-text>(a) the GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref>,</claim-text><claim-text>(b) a long-acting GDF15 fusion protein in which the GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref> is bound to human IgG Fc or a variant thereof, or</claim-text><claim-text>a fusion protein dimer comprising two of the long-acting GDF15 fusion protein of (b).</claim-text></claim-text></claim><claim id="CLM-23-24" num="23-24"><claim-text><b>23</b>.-<b>24</b>. (canceled)</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. A method for treating or preventing diabetes, obesity, dyslipidemia, or metabolic syndrome in an individual in need thereof, comprising:<claim-text>a step of administering, to the individual, an effective amount of<claim-text>(a) the GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref>,</claim-text><claim-text>(b) a long-acting GDF15 fusion protein in which the GDF15 variant of <claim-ref idref="CLM-00001">claim 1</claim-ref> is bound to human IgG Fc or a variant thereof, or</claim-text><claim-text>(c) a fusion protein dimer comprising two of the long-acting GDF15 fusion protein of (b).</claim-text></claim-text></claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. The long-acting GDF15 fusion protein of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the GDF15 variant is bound to the IgG Fc or the variant thereof via a linker, said linker being</claim-text><claim-text><tables id="TABLE-US-00016" num="00016"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="196pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;48)</entry></row><row><entry/><entry>GGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;92)</entry></row><row><entry/><entry>GSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;93)</entry></row><row><entry/><entry>GSGGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;94)</entry></row><row><entry/><entry>GSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;95)</entry></row><row><entry/><entry>GSEEEAEEEAEEEAEEEAEEEAEEEA,</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;96)</entry></row><row><entry/><entry>GSGGSSPTPTPTPTPTPTPTPTPTPT,</entry></row><row><entry/><entry>or</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;97)</entry></row><row><entry/><entry>GSEAAAKEAAAKEAAAKEAAAKEAAAK.</entry></row></tbody></tgroup></table></tables></claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. The long-acting GDF15 fusion protein of <claim-ref idref="CLM-00026">claim 26</claim-ref>, wherein<claim-text>the GDF variant comprises the amino acid sequence of SEQ ID NO: 28 or 30;</claim-text><claim-text>the first polypeptide of the IgG Fc of the variant thereof comprises the sequence of SEQ ID NO: 46;</claim-text><claim-text>the second polypeptide of the IgG Fc of the variant thereof comprises the sequence of SEQ ID NO: 47; and</claim-text><claim-text>the linker consists of the sequence of SEQ ID NO: 95 or 97.</claim-text></claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. The long-acting GDF15 fusion protein of <claim-ref idref="CLM-00026">claim 26</claim-ref>, wherein the long-acting GDF15 fusion protein comprises the amino acid sequence of SEQ ID NO: 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, or 109.</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. A complex comprising the growth differentiation factor-15 (GDF15) variant of <claim-ref idref="CLM-00001">claim 1</claim-ref> and an IgG Fc, said complex being represented by the following formula (II):<claim-text><br/><?in-line-formulae description="In-line Formulae" end="lead"?>IgG Fc-(L)<sub>m</sub>-N-terminal extension domain-core domain&#x2003;&#x2003;(II)<?in-line-formulae description="In-line Formulae" end="tail"?></claim-text><claim-text>wherein m is an integer of 0 or 1,</claim-text><claim-text>L is a linker selected from the group consisting of SEQ ID NOs: 48, 92, 93, 94, 95, 96, and 97,</claim-text><claim-text>IgG Fc comprises the amino acid sequence of SEQ ID NOs: 42, 44, or 46, and</claim-text><claim-text>N-terminal extension domain and core domain are as defined in <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. The complex of <claim-ref idref="CLM-00029">claim 29</claim-ref>, wherein the N-terminal extension domain-core domain comprises any one amino acid sequence selected from the group consisting of SEQ ID NOs: 21 to 39.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The complex of <claim-ref idref="CLM-00029">claim 29</claim-ref>, wherein the complex comprises any one amino acid sequence selected from the group consisting of SEQ ID NOs: 50-91 and 98-109.</claim-text></claim></claims></us-patent-application>